var title_f0_59_944="MP squeeze sign";
var content_f0_59_944=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70187&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Metacarpophalangeal (MP) squeeze sign",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 358px; height: 283px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With one hand placed over the middle of the metacarpal bones to hold them in line (examiner's left hand), pressure is applied to the 2nd and 5th metacarpal heads, forcing all four metacarpal joints together. When a fist is made, the joint lines are located 1/4 to 3/8 inch from the center of the knuckle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_944=[""].join("\n");
var outline_f0_59_944=null;
var title_f0_59_945="Distal tibia fibula fracture";
var content_f0_59_945=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F72158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F72158&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 540px\">",
"   <div class=\"ttl\">",
"    Transverse fracture of the distal tibia and fibula",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 520px; height: 380px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This seven-year-old child sustained distal fractures of the tibia and fibula after being struck by a car while walking. The tibial fracture is comminuted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eglal Shalaby-Rana, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_945=[""].join("\n");
var outline_f0_59_945=null;
var title_f0_59_946="Fungiform papilloma Light";
var content_f0_59_946=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fungiform papilloma of the nasal septum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 382px; height: 266px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph of a fungiform papilloma, an exophytic lesion that arises from the nasal septum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of G Kenneth Haines, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_946=[""].join("\n");
var outline_f0_59_946=null;
var title_f0_59_947="Salter I fracture";
var content_f0_59_947=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81082&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Salter I fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 349px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AP and oblique views of the right ankle. Salter Harris type I fracture of the distal fibula. Notice the lateral malleolar soft tissue swelling with the widening of the fibular physis and a slight medial displacement of the epiphysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David Mathison, MD and Dewesh Agrawal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_947=[""].join("\n");
var outline_f0_59_947=null;
var title_f0_59_948="Phases of diastole";
var content_f0_59_948=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F61186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F61186&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phases of diastole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 382px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_948=[""].join("\n");
var outline_f0_59_948=null;
var title_f0_59_949="Deferoxamine: Patient drug information";
var content_f0_59_949=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Deferoxamine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=see_link\">",
"     see \"Deferoxamine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37894?source=see_link\">",
"     see \"Deferoxamine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Desferal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Desferal&reg;;",
"     </li>",
"     <li>",
"      PMS-Deferoxamine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691625",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of iron when too much is in the body.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3431439",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to get rid of aluminum from the body in long-term kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701900",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to deferoxamine or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703827",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad kidney disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016477\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any eye problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hearing loss, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698492",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have a hearing test before starting this drug and then every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3431480",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before taking multivitamins, natural products, and diet aids. These may have vitamin C in them.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016478\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697959",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of urine to red.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698261",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698200",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Leg cramps.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698247",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Muscle or joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016480\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle, vein, or into the fatty part of the skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as an infusion into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as an infusion under the skin over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016481\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3431441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Most of the time, this drug will be given in a hospital or doctor's office. If stored at home, follow how to store as you were told by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016482\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11716 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-61.234.146.186-C2273CD5CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_949=[""].join("\n");
var outline_f0_59_949=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157271\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157272\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016473\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016472\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016477\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016478\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016480\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016475\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016476\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016481\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016482\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?22/10/22695?source=related_link\">",
"      Deferoxamine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?37/0/37894?source=related_link\">",
"      Deferoxamine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_59_950="Oxacillin: Pediatric drug information";
var content_f0_59_950=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Oxacillin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"    see \"Oxacillin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/56/900?source=see_link\">",
"    see \"Oxacillin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1049081\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Penicillin (Antistaphylococcal)",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11444086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     I.M., I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     For treatment of CNS infection, consider dosages at higher end of range.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA 0-28 days and &lt;1200 g: 50 mg/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &lt;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200-2000 g: 50-100 mg/kg/day in divided doses every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2000 g: 75-150 mg/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     PNA &ge;7 days:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1200-2000 g: 75-150 mg/kg/day in divided doses every 8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;2000 g: 100-200 mg/kg/day in divided doses every 6 hours",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1049074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"      see \"Oxacillin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate infections:",
"     </b>",
"     I.M., I.V.: 100-150 mg/kg/day in divided doses every 6 hours; maximum dose: 4 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     I.M., I.V.: 150-200 mg/kg/day in divided doses every 4-6 hours; maximum dose: 12 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Endocarditis, oxacillin/methicillin-susceptible staphylococci:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Native valve: 200 mg/kg/day in divided doses every 4-6 hours for 6 weeks with gentamicin for the first 3-5 days of therapy (Baddour, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prosthetic valve: 200 mg/kg/day in divided doses every 4-6 hours for &ge;6 weeks with rifampin (same duration as oxacillin) and with gentamicin for the first 2 weeks of therapy (Baddour, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Mild-to-moderate infections:",
"     </b>",
"     I.M., I.V.: 250-500 mg every 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Severe infections:",
"     </b>",
"     I.M., I.V.: 1-2 g every 4-6 hours; maximum dose: 12 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Endocarditis:",
"     </b>",
"     I.V.: 2 g every 4 hours (use with gentamicin and rifampin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prosthetic joint infection:",
"     </b>",
"     I.V.: 2 g every 4 hours with rifampin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Staphylococcus aureus,",
"      </i>",
"     </b>",
"     <b>",
"      methicillin-susceptible infections, including brain abscess, bursitis, erysipelas, mastitis, mastoiditis, osteomyelitis, perinephric abscess, pneumonia, pyomyositis, scalded skin syndrome, toxic shock syndrome:",
"     </b>",
"     I.V.: 2 g every 4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing interval in renal impairment:",
"     </b>",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Clinical practice varies; some clinicians recommend adjustment to the lower range of the usual dosage as based on severity of infection; not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F204167\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed iso-osmotic solution: 1 g (50 mL); 2 g (50 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution: 1 g, 2 g, 10 g",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F204151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1049084\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M. injection: Reconstitute each gram of oxacillin with 5.7 mL of SWI to make a 167 mg/mL solution; shake well until a clear solution is obtained. Administer by deep I.M. injection into a large muscle mass (eg, gluteus maximus).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: May be administered by direct I.V. injection over 10 minutes at a maximum concentration of 100 mg/mL or by intermittent I.V. infusion over 15-30 minutes at a final concentration &le;40 mg/mL; for peripheral administration, some centers infuse oxacillin at a concentration of 20 mg/mL over 60 minutes (Dahlgren, 1997)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F204222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 40 10% in dextrose, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      10",
"     </sub>",
"     W, hetastarch 6%, LR;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, cyclophosphamide, cyclosporine, diltiazem, famotidine, fluconazole, foscarnet, heparin, hydrocortisone sodium succinate, hydromorphone, labetalol, levofloxacin, magnesium sulfate, meperidine, methotrexate, milrinone, morphine, oxytocin, potassium chloride, tacrolimus, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Caffeine citrate, sodium bicarbonate, verapamil.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Doxapram, vitamin B complex with C.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Incompatible:",
"     </b>",
"     Caffeine citrate.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1049078\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Premixed infusions: Store in a freezer at &le;-20&deg;C (-4&deg;F). Thaw at room temperature or under refrigeration only. Thawed bags are stable for 21 days under refrigeration or 48 hours at room temperature. Do not refreeze.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vials: Store dry powder at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); reconstituted parenteral solution (250 mg/1.5 mL) is stable for 3 days at room temperature and 7 days when refrigerated or 12 weeks when frozen. For I.V. infusion in NS (10-100 mg/mL), solution is stable for 4 days at room temperature and 7 days when refrigerated; for I.V. infusion in D",
"     <sub>",
"      5",
"     </sub>",
"     W (10-30 mg/mL), solution is stable for 4 days when refrigerated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral solutions are incompatible with aminoglycosides and tetracyclines.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1049083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of bacterial infections, such as osteomyelitis, septicemia, endocarditis, and CNS infections, due to susceptible penicillinase-producing strains of",
"     <i>",
"      Staphylococcus",
"     </i>",
"     [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F204221\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Fever",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, eosinophilia, leukopenia, neutropenia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatotoxicity, AST increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute interstitial nephritis, hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Serum sickness-like reactions",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1049087\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to oxacillin, other penicillins, or any component; premixed solutions: Hypersensitivity to corn or corn products",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1049073\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hypersensitivity to cephalosporins, severe renal impairment; dosage modification required in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1049072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serious and occasionally fatal hypersensitivity (anaphylactoid) reactions have been reported in patients on penicillin therapy, especially with a history of beta-lactam hypersensitivity, history of sensitivity to multiple allergens, or previous IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria); immediate treatment for an anaphylactic reaction should be available during administration. In neonates, elimination rate is decreased due to immature renal function; dosage adjustment is needed; hematuria and azotemia have occurred in neonates and infants receiving high-dose oxacillin. Cases of acute hepatitis and reversible elevations of serum transaminases have been reported with oxacillin. In adult and pediatric patients receiving outpatient antibiotic therapy, oxacillin has been shown to have a significantly higher incidence of adverse events as compared to nafcillin and other antibiotics in comparator group; adverse events reported include rash, leukopenia, and hepatitis; onset after 2-3 weeks of therapy; patients should be monitored periodically throughout therapy (Dahlgren, 1997; Faden, 2009; Maraqa, 2002; Vial, 1997). Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F204160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Penicillins may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Penicillins may decrease serum concentrations of the active metabolite(s) of Mycophenolate. This effect appears to be the result of impaired enterohepatic recirculation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Penicillins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: May diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Penicillins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F204163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F204176\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Oxacillin is distributed into the amniotic fluid and is detected in cord blood. Maternal use of penicillins has generally not resulted in an increased risk of adverse fetal effects.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1049080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic CBC with differential, urinalysis, BUN, serum creatinine, AST and ALT; number and type of stools/day for diarrhea; observe I.V. site for extravasation",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1049071\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Interferes with bacterial cell wall synthesis during active multiplication by binding to one or more of the penicillin-binding proteins; inhibits the final transpeptidation step of peptidoglycan synthesis causing cell wall death and resultant bactericidal activity against susceptible bacteria",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1049086\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into bile, pleural, synovial, and pericardial fluids and into lungs and bone; penetrates the blood-brain barrier only when meninges are inflamed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~94%; primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to active and inactive metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neonates 8-15 days: 1.6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants, Children 1 week to 2 years: 0.9-1.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: 0.3-0.8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: I.M.: Within 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine and feces (small amounts as unchanged drug and metabolites)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not dialyzable (0% to 5%)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F13335172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/56/900?source=see_link\">",
"      see \"Oxacillin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Report any redness, swelling, burning, or pain at injection site; report any difficulty in swallowing or respiration. Contact physician if watery and bloody stools occur.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1049088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium content: 1 g injection: 2.5 mEq",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Baddour LM, Wilson WR, Bayer AS, et al, \"Infective Endocarditis: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Statement for Healthcare Professionals From the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: Endorsed by the Infectious Diseases Society of America,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2005, 111(23):e394-434.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/950/abstract-text/15956145/pubmed\" id=\"15956145\" target=\"_blank\">",
"        15956145",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlgren AF, \"Adverse Drug Reactions in Home Care Patients Receiving Nafcillin or Oxacillin,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1997, 54(10):1176-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/950/abstract-text/9161625/pubmed\" id=\"9161625\" target=\"_blank\">",
"        9161625",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Faden D and Faden HS, \"The High Rate of Adverse Drug Events in Children Receiving Prolonged Outpatient Parenteral Antibiotic Therapy for Osteomyelitis,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 2009, 28(6):539-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/950/abstract-text/19483522/pubmed\" id=\"19483522\" target=\"_blank\">",
"        19483522",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maraqa NF, Gomez MM, Rathore MH, et al, \"Higher Occurrence of Hepatotoxicity and Rash in Patients Treated With Oxacillin, Compared With Those Treated With Nafcillin and Other Commonly Used Antimicrobials,\"",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2002, 34(1):50-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/950/abstract-text/11731945/pubmed\" id=\"11731945\" target=\"_blank\">",
"        11731945",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Olans RN and Weiner LB, \"Reversible Oxacillin Hepatotoxicity,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1976, 89(5):835-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/950/abstract-text/978335/pubmed\" id=\"978335\" target=\"_blank\">",
"        978335",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prober CG, Stevenson DK, and Benitz WE, \"The Use of Antibiotics in Neonates Weighing Less Than 1200 Grams,\"",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1990, 9(2):111-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/950/abstract-text/2179837/pubmed\" id=\"2179837\" target=\"_blank\">",
"        2179837",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Robinson DC, Cookson TL, and Grisafe JA, \"Concentration Guidelines for Parenteral Antibiotics in Fluid-Restricted Patients,\"",
"      <i>",
"       Drug Intell Clin Pharm",
"      </i>",
"      , 1987, 21(12):985-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/950/abstract-text/3428165/pubmed\" id=\"3428165\" target=\"_blank\">",
"        3428165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Vial T, Biour M, Descotes J, et al, \"Antibiotic-Associated Hepatitis: Update From 1990,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1997, 31(2):204-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/950/abstract-text/9034423/pubmed\" id=\"9034423\" target=\"_blank\">",
"        9034423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12663 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.98.179-4838B967EE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_950=[""].join("\n");
var outline_f0_59_950=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049081\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11444086\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049074\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204167\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204151\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049084\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204222\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049078\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049083\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204221\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049087\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049073\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049072\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299797\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204160\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204163\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204176\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049080\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049071\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049086\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13335172\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1049088\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12663\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12663|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=related_link\">",
"      Oxacillin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/56/900?source=related_link\">",
"      Oxacillin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_59_951="Hysterosc myomectomy chips";
var content_f0_59_951=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F53091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F53091&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hysteroscopic myomectomy: copious leiomyoma shavings (chips)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This picture depicts multiple leiomyoma shavings (chips) that were removed during a hysteroscopic myomectomy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Linda D Bradley, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_951=[""].join("\n");
var outline_f0_59_951=null;
var title_f0_59_952="Dose adj pharmacogenetics";
var content_f0_59_952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F78144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F78144&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 595px\">",
"   <div class=\"ttl\">",
"    Examples of dose adjustments based on PGDx",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 575px; height: 463px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The influence of genetic polymorphisms in cytochrome P450 enzymes CYP2D6, CYP2C19 and CYP2C9, thiopurine",
"    <em>",
"     S",
"    </em>",
"    -methyltransferase (TPMT) and",
"    <em>",
"     N",
"    </em>",
"    -acetyltransferase type 2 (NAT2) is expressed as subpopulation-specific dosages, according to the difference in pharmacokinetic parameters from clinical studies. The dose adjustments illustrated by the bars in this graph are based on differences in dose-related pharmacokinetic parameters (clearance, AUC, STEADY STATE CONCENTRATION) caused by particular genotypes and are calculated using the methods described earlier. Substantial adjustments need to be made to drug dose to achieve the same level of drug exposure in individuals with different genotypes.",
"    <div class=\"footnotes\">",
"     AUC: area under the curve; EM: extensive metabolizer; IA: intermediate acetylator; IM: intermediate metabolizer; PM: poor metabolizer; RA: rapid acetylator; SA: slow acetylator; UM: ultra-rapid metabolizer.",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted by permission from Macmillan Publishers LTD: Kirchheiner J, Fuhr U, Borckmoller J. Pharmacogenetics-based therapeutic recommendations--ready for clinical practie? Nat Rev Drug Discov 2005; 4:639. Copyright &copy; 2005.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_952=[""].join("\n");
var outline_f0_59_952=null;
var title_f0_59_953="Vinorelbine: Drug information";
var content_f0_59_953=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Vinorelbine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?8/8/8325?source=see_link\">",
"    see \"Vinorelbine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F234356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Navelbine&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F234357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Navelbine&reg;;",
"     </li>",
"     <li>",
"      Vinorelbine Injection, USP;",
"     </li>",
"     <li>",
"      Vinorelbine Tartrate for Injection",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F234394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antineoplastic Agent, Natural Source (Plant) Derivative;",
"     </li>",
"     <li>",
"      Antineoplastic Agent, Vinca Alkaloid",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F234361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Details concerning dosing in combination regimens should also be consulted. Adults: I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonsmall cell lung cancer (NSCLC):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Single-agent therapy:",
"     </i>",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 7 days until disease progression or unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Combination therapy:",
"     </i>",
"     25-30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 7 days (in combination with cisplatin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Unlabeled dosing:",
"     </i>",
"     25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 8 every 21 days (in combination with cisplatin and cetuximab) for up to 6 cycles (Pirker, 2009)",
"     <b>",
"      or",
"     </b>",
"     25-30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1, 8, and 15 every 28 days (in combination with gemcitabine) for 6 cycles",
"     <b>",
"      or",
"     </b>",
"     until disease progression or unacceptable toxicity (Herbst, 2002; Greco, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Breast cancer, metastatic (unlabeled use):",
"     </b>",
"     I.V.: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 7 days (as a single agent) until disease progression or unacceptable toxicity (Zelek, 2001)",
"     <b>",
"      or",
"     </b>",
"     25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 7 days (in combination with trastuzumab) until disease progression or unacceptable toxicity (Burstein, 2001)",
"     <b>",
"      or",
"     </b>",
"     30 or 35 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 8 every 21 days (in combination with trastuzumab) until disease progression or unacceptable toxicity (Andersson, 2011)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cervical cancer (unlabeled use):",
"     </b>",
"     I.V.: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 8 of a of a 21-day treatment cycle (Muggia, 2004; Muggia, 2005)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hodgkin lymphoma, relapsed or refractory (unlabeled use):",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      GVD regimen:",
"     </i>",
"     15 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (post-transplant patients) or 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (transplant-na&iuml;ve patients) on days 1 and 8 of a 21-day cycle (in combination with gemcitabine and doxorubicin liposomal) for 2 to 6 cycles (Bartlett, 2007 )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      IGEV regimen:",
"     </i>",
"     20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on day 1 of a 21-day cycle (in combination with ifosfamide, mesna, gemcitabine, and prednisolone) for 4 cycles (Santoro, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Malignant pleural mesothelioma (unlabeled use):",
"     </b>",
"     I.V.: 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 60 mg) every 7 days per 6&ndash;week treatment cycle, continue until disease progression (Stebbing, 2009)",
"     <b>",
"      or",
"     </b>",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     (maximum dose: 60 mg) every 7 days for 6 weeks, off 2 weeks, then repeat cycle (Muers, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ovarian cancer, relapsed (unlabeled use):",
"     </b>",
"     I.V.: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 7 days (Bajetta, 1996)",
"     <b>",
"      or",
"     </b>",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 8 of a 21-day treatment cycle (Rothenberg, 2004) until disease progression or unacceptable toxicity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Salivary gland cancer, recurrent (unlabeled use):",
"     </b>",
"     I.V.: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     on days 1 and 8 of a 21-day cycle (in combination with cisplatin) for up to 6 cycles (Airoldi, 2001)",
"     <b>",
"      or",
"     </b>",
"     30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 7 days (monotherapy) for 9 weeks (Airoldi, 2001)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Small cell lung cancer, refractory (unlabeled use):",
"     </b>",
"     I.V.: 25 or 30 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     every 7 days until disease progression or unacceptable toxicity (Furuse, 1996; Jessem, 1993)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Soft tissue sarcoma, advanced (unlabeled use):",
"     </b>",
"     I.V.: 25 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     days 1 and 8 of a 21-day treatment cycle (in combination with gemcitabine) until disease progression or unacceptable toxicity (Dileo, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing in obesity:",
"     </b>",
"     <i>",
"      ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer:",
"     </i>",
"     Utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F234362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F234363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Renal insufficiency: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis: Initial: I.V.: Reduce dose to 20 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /week; administer either after dialysis (on dialysis days) or on nondialysis days (Janus, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F234364\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     In patients with concurrent hematologic toxicity and hepatic impairment, administer the lower of the doses determined from the adjustment recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Administer with caution in patients with hepatic insufficiency. In patients who develop hyperbilirubinemia during treatment with vinorelbine, the dose should be adjusted for total bilirubin as follows:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin &le;2 mg/dL: Administer 100% of dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin 2.1-3 mg/dL: Administer 50% of dose (Ecklund, 2005; Floyd, 2006; Superfin, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Serum bilirubin &gt;3 mg/dL: Administer 25% of dose (Ecklund, 2005; Floyd, 2006; Superfin, 2006)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Patients (breast cancer) with extensive liver metastases (&gt;75% of liver volume): Administer 50% of dose (Ecklund, 2005; Superfin, 2006)",
"    </p>",
"   </div>",
"   <div class=\"block dot drugH1Div\" id=\"F5720704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adjustment for Toxicity",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     In patients with concurrent hematologic toxicity and hepatic impairment, administer the lower of the doses determined from the adjustment recommendations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hematological toxicity (based on granulocyte counts):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Granulocytes &ge;1500 cells/mm",
"      <sup>",
"       3",
"      </sup>",
"     </i>",
"     on day of treatment: Administer 100% of starting dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Granulocytes 1000-1499 cells/mm",
"      <sup>",
"       3",
"      </sup>",
"     </i>",
"     on day of treatment: Administer 50% of starting dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Granulocytes &lt;1000 cells/mm",
"      <sup>",
"       3",
"      </sup>",
"     </i>",
"     on day of treatment: Do not administer. Repeat granulocyte count in 1 week. If 3 consecutive doses are held because granulocyte count is &lt;1000 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"     , discontinue vinorelbine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Adjustment:",
"     </b>",
"     For patients who, during treatment, have experienced fever or sepsis while granulocytopenic or had 2 consecutive weekly doses held due to granulocytopenia, subsequent doses of vinorelbine should be:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     75% of starting dose for granulocytes &ge;1500 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     37.5% of starting dose for granulocytes 1000-1499 cells/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for neurotoxicity:",
"     </b>",
"     Neurotoxicity &ge;grade 2: Discontinue treatment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment for other adverse events:",
"     </b>",
"     Severe adverse events: Reduce dose or discontinue treatment",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F234335\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution: 10 mg/mL (1 mL [DSC], 5 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]: 10 mg/mL (1 mL, 5 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Navelbine&reg;: 10 mg/mL (1 mL, 5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F234320\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F234338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      For I.V. use only;  FATAL IF GIVEN INTRATHECALLY.",
"     </b>",
"     Administer as a direct intravenous push or rapid bolus, over 6-10 minutes (up to 30 minutes). Longer infusions may increase the risk of pain and phlebitis. Intravenous doses should be followed by at least 75-125 mL of saline or D",
"     <sub>",
"      5",
"     </sub>",
"     W to reduce the incidence of phlebitis and inflammation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     Vesicant; avoid extravasation. Assure proper needle or catheter position prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Extravasation management:",
"     </b>",
"     If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do",
"     <b>",
"      NOT",
"     </b>",
"     flush the line); initiate hyaluronidase antidote; apply dry warm compresses for 20 minutes 4 times a day for 1-2 days; elevate extremity. Hyaluronidase: If needle/cannula still in place, administer 1-6 mL hyaluronidase (150 units/mL) into the existing I.V. line; the usual dose is 1 mL hyaluronidase for each 1 mL of extravasated drug (Perez Fidalgo, 2012; Schulmeister, 2011). If needle/cannula has been removed, inject 1-6 mL (150 units/mL) subcutaneously in a clock wise manner using 1mL for 1 mL of drug extravasated (Schulmeister, 2011) or administer 1 mL  (150 units/mL) as 5 separate 0.2 mL injections (25-gauge needle) subcutaneously into the extravasation site (Polovich, 2009). Remaining portion of the vincristine dose should be infused through a separate vein.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F234400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, NS,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Amikacin, aztreonam, bleomycin, bumetanide, buprenorphine, butorphanol, calcium gluconate, carboplatin, carmustine, cefotaxime, ceftazidime, chlorpromazine, cimetidine, cisplatin, clindamycin, cyclophosphamide, cytarabine, dacarbazine, dactinomycin, daunorubicin HCl, dexamethasone sodium phosphate, diphenhydramine, doxorubicin, doxorubicin liposome, doxycycline, droperidol, enalaprilat, etoposide, famotidine, filgrastim, floxuridine, fluconazole, fludarabine, gallium nitrate, gemcitabine, gentamicin, granisetron, haloperidol lactate, hydrocortisone sodium succinate, hydromorphone, hydroxyzine HCl, idarubicin, ifosfamide, imipenem/cilastatin, lorazepam, mannitol, mechlorethamine, melphalan, meperidine, mesna, methotrexate, metoclopramide, metronidazole, mitoxantrone, morphine, nalbuphine, ondansetron, oxaliplatin, potassium chloride, prochlorperazine, promethazine, ranitidine, streptozocin, teniposide, ticarcillin/clavulanate, tobramycin, vancomycin, vinblastine, vincristine, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Acyclovir, allopurinol, aminophylline, amphotericin B, amphotericin B cholesteryl sulfate complex, ampicillin, cefazolin, cefotetan, ceftriaxone, cefuroxime, fluorouracil, furosemide, ganciclovir, methylprednisolone sodium succinate, mitomycin, piperacillin, sodium bicarbonate, thiotepa, trimethoprim/sulfamethoxazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Heparin.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F234336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of nonsmall cell lung cancer (NSCLC)",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F234390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of breast cancer (metastatic), cervical cancer (persistent or recurrent), Hodgkin lymphoma (relapsed or refractory), ovarian cancer (relapsed), malignant pleural mesothelioma, salivary gland cancer, small cell lung cancer, and soft tissue sarcoma (advanced)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F234403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vinorelbine may be confused with vinBLAStine, vinCRIStine",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Vinorelbine is intended",
"       <b>",
"        for I.V. use only",
"       </b>",
"       : Inadvertent intrathecal administration of other vinca alkaloids has resulted in death. Syringes containing vinorelbine should be labeled",
"       <b>",
"        &ldquo;For I.V. use only. Fatal if given intrathecally.&rdquo;",
"       </b>",
"       Vinorelbine should",
"       <b>",
"        NOT",
"       </b>",
"       be prepared during the preparation of any intrathecal medications. After preparation, keep vinorelbine in a location",
"       <b>",
"        away",
"       </b>",
"       from the separate storage location recommended for intrathecal medications.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F234392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reported with single-agent therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Alopecia (12% to 30%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (31% to 44%; grade 3: 1% to 2%), constipation (35%; grade 3: 3%), vomiting (20% to 31%; grade 3: 1% to 2%), diarrhea (12% to 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Leukopenia (83% to 92%; grade 4: 6% to 15%), granulocytopenia (90%; grade 4: 36%; nadir: 7-10 days; recovery 14-21 days), neutropenia (85%; grade 4: 28%), anemia (83%; grades 3/4: 9%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: AST increased (67%; grade 3: 5%; grade 4: 1%), total bilirubin increased (5% to 13%; grade 3: 4%; grade 4: 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (22% to 28%; includes erythema, vein discoloration), injection site pain (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Weakness (36%), peripheral neuropathy (25%; grade 3: 1%; grade 4: &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine increased (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Paralytic ileus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenic fever/sepsis (8%; grade 4: 4%), thrombocytopenia (3% to 5%; grades 3/4: 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Phlebitis (7% to 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Loss of deep tendon reflexes (&lt;5%), myalgia (&lt;5%), arthralgia (&lt;5%), jaw pain (&lt;5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Otic: Ototoxicity (&le;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Abdominal pain, allergic reactions, anaphylaxis, angioedema, back pain, DVT, dysphagia, esophagitis, flushing, gait instability, headache, hemolytic uremic syndrome, hemorrhagic cystitis, hyper-/hypotension, hyponatremia, intestinal necrosis, intestinal obstruction, intestinal perforation, interstitial pulmonary changes, local rash, local urticaria, MI (rare), mucositis, muscle weakness, myocardial ischemia, pancreatitis, paralytic ileus, pneumonia, pruritus, pulmonary edema, pulmonary embolus, radiation recall (dermatitis, esophagitis), skin blistering, syndrome of inappropriate ADH secretion, tachycardia, thromboembolic events, thrombotic thrombocytopenic purpura, tumor pain, urticaria, vasodilation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F234341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Pretreatment granulocyte counts &lt;1000/mm",
"     <sup>",
"      3",
"     </sup>",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F234324\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone marrow suppression:",
"     <b>",
"      [U.S. Boxed Warning]: Severe granulocytopenia may occur with treatment; granulocyte counts should be &ge;1000/mm",
"      <sup>",
"       3",
"      </sup>",
"      prior to treatment initiation; dosage adjustment may be required based on blood counts (monitor blood counts prior to each dose).",
"     </b>",
"     Granulocytopenia is a dose-limiting toxicity; monitor closely for infections and/or fever in patients with severe granulocytopenia. Use with extreme caution in patients with compromised marrow reserve due to prior chemotherapy or radiation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal effects: May cause severe constipation (grade 3-4), paralytic ileus, intestinal obstruction, necrosis, and/or perforation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuropathy: May cause new-onset or worsening of pre-existing neuropathy; use with caution in patients with neuropathy. Monitor for new or worsening sign/symptoms of neuropathy. Dosage adjustment required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pulmonary toxicity: Fatal cases of interstitial pulmonary changes and ARDS have been reported with single-agent therapy (mean onset of symptoms: 1 week). Promptly evaluate changes in baseline pulmonary symptoms or any new-onset pulmonary symptoms (eg, dyspnea, cough, hypoxia). Acute shortness of breath and severe bronchospasm have been reported with vinca alkaloids, usually when used in combination with mitomycin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Vinorelbine elimination is predominantly hepatic. While there is no evidence that toxicity is enhanced in patients with elevated transaminases, use with caution in patients with severe hepatic injury or impairment; dosage modification required for elevated total bilirubin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Radiation therapy: May have radiosensitizing effects with prior or concurrent radiation therapy; radiation recall reactions may occur in patients who have received prior radiation therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     ; avoid eye contamination (exposure may cause severe irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced physician:",
"     <b>",
"      [U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extravasation:",
"     <b>",
"      [U.S. Boxed Warning]: Avoid extravasation; ensure proper catheter or needle position prior to (and during) infusion; extravasation my cause local tissue necrosis and/or thrombophlebitis.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; NOT for intrathecal use:",
"     <b>",
"      [U.S. Boxed Warning]: For I.V. use only; intrathecal administration of other vinca alkaloids has resulted in death. If dispensed in a syringe, should be labeled &ldquo;for intravenous use only - fatal if given intrathecally\".",
"     </b>",
"     Vinorelbine should",
"     <b>",
"      NOT",
"     </b>",
"     be prepared during the preparation of any intrathecal medications. After preparation, keep vinorelbine in a location",
"     <b>",
"      away",
"     </b>",
"     from the separate storage location recommended for intrathecal medications.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F234388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F234329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the adverse/toxic effect of Vinorelbine. Specifically, the combination may be associated with a higher risk of granulocytopenia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for agranulocytosis may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: May enhance the neutropenic effect of Vinorelbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: May enhance the adverse/toxic effect of Vinorelbine. Itraconazole may increase the serum concentration of Vinorelbine. Management: Monitor for increased toxic effects of vinorelbine if itraconazole is being received/initiated/dose increased.  Decreased vinorelbine doses may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Macrolides may also increase the distribution of Vinca Alkaloids into certain cells and/or tissues. Management: Consider an alternative to using a macrolide antibiotic when possible in order to avoid the potential for increased vinca alkaloid toxicity.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MitoMYcin (Systemic): Antineoplastic Agents (Vinca Alkaloids) may enhance the adverse/toxic effect of MitoMYcin (Systemic). Specifically, the risk of pulmonary toxicity may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel: May enhance the neurotoxic effect of Vinorelbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PACLitaxel (Protein Bound): May enhance the neurotoxic effect of Vinorelbine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Posaconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids). Management: Consider vinca alkaloid dose adjustment.  Specific dose adjustment guidelines are not currently available.  Monitor response to vinca alkaloid therapy, including development of vinca alkaloid toxicities (e.g., gastrointestinal toxicity, neurotoxicity).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Vaccinial infections may develop. Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May enhance the adverse/toxic effect of Antineoplastic Agents (Vinca Alkaloids). Voriconazole may increase the serum concentration of Antineoplastic Agents (Vinca Alkaloids).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F234353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Avoid St John's wort (may decrease vinorelbine levels).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F234331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5720023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have demonstrated embryotoxicity, fetotoxicity, decreased fetal weight, and delayed ossification. May cause fetal harm if administered during pregnancy. Women of childbearing potential should avoid becoming pregnant during vinorelbine treatment.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F234370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5720025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if vinorelbine is excreted in breast milk. Due to the potential for serious adverse reactions in the nursing infant, breast-feeding should be discontinued during treatment.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Navelbine Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $42.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (5 mL): $210.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Vinorelbine Tartrate Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/mL (1 mL): $30.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/5 mL (5 mL): $144.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F234333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC with differential and platelet count (prior to each dose, and after treatment), hepatic function tests; monitor for new-onset pulmonary symptoms (or worsening from baseline); monitor for neuropathy (new or worsening symptoms; monitor infusion site ; monitor for signs symptoms of constipation/ileus",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F234343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Filcrin (UY);",
"     </li>",
"     <li>",
"      Navelbin (HN);",
"     </li>",
"     <li>",
"      Navelbine (AE, AR, AT, AU, BB, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CY, CZ, DE, DK, EE, EG, ES, FI, FR, GB, GR, GY, ID, IE, IL, IQ, IR, IT, JM, JO, KP, KW, LB, LU, LY, MX, MY, NL, NO, NZ, OM, PK, PL, QA, RU, SA, SE, SR, SY, TH, TR, TT, TW, YE);",
"     </li>",
"     <li>",
"      Viessia (TH);",
"     </li>",
"     <li>",
"      Vilne (EC);",
"     </li>",
"     <li>",
"      Vinbine (IN);",
"     </li>",
"     <li>",
"      Vinorgen (PE, PY);",
"     </li>",
"     <li>",
"      Vinotel (PH);",
"     </li>",
"     <li>",
"      Zinavin (CO)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F234323\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Semisynthetic vinca alkaloid which binds to tubulin and inhibits microtubule formation, therefore, arresting the cell at metaphase by disrupting the formation of the mitotic spindle; it is specific for the M and S phases. Vinorelbine may also interfere with nucleic acid and protein synthesis by blocking glutamic acid utilization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F234340\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 25-40 L/kg; binds extensively to human platelets and lymphocytes (80% to 91%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 80% to 91%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic, via CYP3A4, to two metabolites, deacetylvinorelbine (active) and vinorelbine N-oxide",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Triphasic: Terminal: 28-44 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (46%); urine (18%, 10% to 12% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Airoldi M, Pedani F, Succo G, et al, &ldquo;Phase II Randomized Trial Comparing Vinorelbine versus Vinorelbine Plus Cisplatin in Patients With Recurrent Salivary Gland Malignancies,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2001, 91(3):541-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/11169936/pubmed\" id=\"11169936\" target=\"_blank\">",
"        11169936",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andersson M, Lidbrink E, Bjerre K, et al, &ldquo;Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab as First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2011, 29(3):264-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/21149659/pubmed\" id=\"21149659\" target=\"_blank\">",
"        21149659",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bajetta E, Di Leo A, Biganzoli L, et al, &ldquo;Phase II Study of Vinorelbine in Patients With Pretreated Advanced Ovarian Cancer: Activity in Platinum-Resistant Disease,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 1996, 14(9):2546-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/8823334/pubmed\" id=\"8823334\" target=\"_blank\">",
"        8823334",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bartlett NL, Niedzwiecki D, Johnson JL, et al, \"Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin (GVD), a Salvage Regimen in Relapsed Hodgkin's Lymphoma: CALGB 59804,\"",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2007, 18(6):1071-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/17426059/pubmed\" id=\"17426059\" target=\"_blank\">",
"        17426059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Budman DR, &ldquo;Vinorelbine (Navelbine&reg;): A Third-Generation Vinca Alkaloid,&rdquo;",
"      <i>",
"       Cancer Invest",
"      </i>",
"      , 1997, 15(5);475-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/3179771/pubmed\" id=\"3179771\" target=\"_blank\">",
"        3179771",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burstein HJ, Kuter I, Campos SM, et al, \"Clinical Activity of Trastuzumab and Vinorelbine in Women With HER2-Overexpressing Metastatic Breast Cancer,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2001, 19(10):2722-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/11352965/pubmed\" id=\"11352965\" target=\"_blank\">",
"        11352965",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Casanova M, Ferrari A, Bisogno G, et al, &ldquo;Vinorelbine and Low-Dose Cyclophosphamide in the Treatment of Pediatric Sarcomas: Pilot Study for the Upcoming European Rhabdomyosarcoma Protocol,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2004, 101(7):1664-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/15378498/pubmed\" id=\"15378498\" target=\"_blank\">",
"        15378498",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Casanova M, Ferrari A, Spreafico F, et al, &ldquo;Vinorelbine in Previously Treated Advanced Childhood Sarcomas: Evidence of Activity in Rhabdomyosarcoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 94(12):3263-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/12115359/pubmed\" id=\"12115359\" target=\"_blank\">",
"        12115359",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dileo P, Morgan JA, Zahrieh D, et al, &ldquo;Gemcitabine and Vinorelbine Combination Chemotherapy for Patients With Advanced Soft Tissue Sarcomas,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2007, 109(9):1863-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/17385194/pubmed\" id=\"17385194\" target=\"_blank\">",
"        17385194",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ecklund JW, Trifilio S, and Mulcahy MF, &ldquo;Chemotherapy Dosing in the Setting of Liver Dysfunction,&rdquo;",
"      <i>",
"       Oncology (Williston Park)",
"      </i>",
"      , 2005, 19(8):1057-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/16131047/pubmed\" id=\"16131047\" target=\"_blank\">",
"        16131047",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ejlertsen B, Mouridsen HT, Langkjer ST, et al, &ldquo;Phase III Study Oof Intravenous Vinorelbine in Combination With Epirubicin versus  Epirubicin Alone in Patients With Advanced Breast Cancer: A Scandinavian Breast Group Trial (SBG9403),&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2004, 22(12):2313-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/15197192/pubmed\" id=\"15197192\" target=\"_blank\">",
"        15197192",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Floyd JD, Nguyen DT, Lobins RL, et al, &ldquo;Cardiotoxicity of Cancer Therapy,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2005, 23(30):7685-96.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/16234530/pubmed\" id=\"16234530\" target=\"_blank\">",
"        16234530",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Furuse K, Kubota K, Kawahara M, et al, &ldquo;Phase II Study of Vinorelbine in Heavily Previously Treated Small Cell Lung Cancer. Japan Lung Cancer Vinorelbine Study Group,&rdquo;",
"      <i>",
"       Oncology",
"      </i>",
"      , 1996, 53(2):169-172.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/8604245/pubmed\" id=\"8604245\" target=\"_blank\">",
"        8604245",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Greco FA, Spigel DR, Kuzur ME, et al, &ldquo;Paclitaxel/Carboplatin/Gemcitabine versus Gemcitabine/Vinorelbine in Advanced Non-Small-Cell Lung Cancer: A Phase II/III Study of the Minnie Pearl Cancer Research Network,&rdquo;",
"      <i>",
"       Clin Lung Cancer",
"      </i>",
"      , 2007, 8(8):483-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/17922972/pubmed\" id=\"17922972\" target=\"_blank\">",
"        17922972",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2012, 30(13):1553-61.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/22473167/pubmed\" id=\"22473167\" target=\"_blank\">",
"        22473167",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Herbst RS, Khuri FR, Lu C, et al, &ldquo;The Novel and Effective Nonplatinum, Nontaxane Combination of Gemcitabine and Vinorelbine in Advanced Nonsmall Cell Lung Carcinoma: Potential for Decreased Toxicity and Combination With Biological Therapy,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2002, 95(2):340-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/12124835/pubmed\" id=\"12124835\" target=\"_blank\">",
"        12124835",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jacobson JO, Polovich M, McNiff KK, et al, &ldquo;American Society of Clinical Oncology/ Oncology Nursing Society Chemotherapy Administration Safety Standards,&rdquo;",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(32):5469-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/19786650/pubmed\" id=\"19786650\" target=\"_blank\">",
"        19786650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Janus N, Thariat J, Boulanger H, et al, &ldquo;Proposal for Dosage Adjustment and Timing of Chemotherapy in Hemodialyzed Patients,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2010, 21(7):1395-403.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/20118214/pubmed\" id=\"20118214\" target=\"_blank\">",
"        20118214",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jassem J, Karnicka-Mlodkowska H, van Pottelsberghe C, et al, &ldquo;Phase II Study of Vinorelbine (Navelbine) in Previously Treated Small Cell Lung Cancer Patients. EORTC Lung Cancer Cooperative Group,&rdquo;",
"      <i>",
"       Eur J Cancer",
"      </i>",
"      , 1993, 29(12):1720-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/8398301/pubmed\" id=\"8398301\" target=\"_blank\">",
"        8398301",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson SA, Harper P, Hortobagyi GN, et al, &ldquo;Vinorelbine: An Overview,&rdquo;",
"      <i>",
"       Cancer Treat Rev",
"      </i>",
"      , 1996, 22(2):127-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/8665565/pubmed\" id=\"8665565\" target=\"_blank\">",
"        8665565",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jones SF and Burris HA 3d, &ldquo;Vinorelbine: A New Antineoplastic Drug for the Treatment of Nonsmall Cell Lung Cancer,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 1996, 30(5):501-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/8740332/pubmed\" id=\"8740332\" target=\"_blank\">",
"        8740332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      LeVeque D and Jehl F, &ldquo;Clinical Pharmacokinetics of Vinorelbine,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1996, 31(3):184-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/8877249/pubmed\" id=\"8877249\" target=\"_blank\">",
"        8877249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monk BJ, Sill MW, McMeekin DS, et al, \"Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study,\"",
"      <i>",
"       J Clin Oncol",
"      </i>",
"      , 2009, 27(28):4649-55.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/19720909/pubmed\" id=\"19720909\" target=\"_blank\">",
"        19720909",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morgan C, Tillett T, Braybrooke J, et al, &ldquo;Management of Uncommon Chemotherapy-Induced Emergencies,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2011, 12(8):806-14.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/21276754/pubmed\" id=\"21276754\" target=\"_blank\">",
"        21276754",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Muers MF, Stephens RJ, Fisher P, et al, &ldquo;Active Symptom Control With or Without Chemotherapy in the Treatment of Patients With Malignant Pleural Mesothelioma (MS01): A Multicentre Randomised Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2008, 371(9625):1685-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/18486741/pubmed\" id=\"18486741\" target=\"_blank\">",
"        18486741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Muggia FM, Blessing JA, Method M, et al, &ldquo;Evaluation of Vinorelbine in Persistent or Recurrent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2004, 92(2):639-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/14766259/pubmed\" id=\"14766259\" target=\"_blank\">",
"        14766259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Muggia FM, Blessing JA, Waggoner S, et al, &ldquo;Evaluation of Vinorelbine in Persistent or Recurrent Nonsquamous Carcinoma of the Cervix: A Gynecologic Oncology Group Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2005, 96(1):108-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/15589588/pubmed\" id=\"15589588\" target=\"_blank\">",
"        15589588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo;",
"      <i>",
"       Ann Oncol",
"      </i>",
"      , 2012, 23(Suppl 7):167-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/22997449/pubmed\" id=\"22997449\" target=\"_blank\">",
"        22997449",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pirker R, Pereira JR, Szczesna A, et al, &ldquo;Cetuximab Plus Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer (FLEX): An Open-Label Randomised Phase III Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 373(9674):1525-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/19410716/pubmed\" id=\"19410716\" target=\"_blank\">",
"        19410716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Polovich M, Whitford JN and Olsen M,",
"      <i>",
"       Chemotherapy and Biotherapy Guidelines and Recommendations for Practice",
"      </i>",
"      , 3rd ed, Pittsburgh, PA: Oncology Nursing Society, 2009.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rothenberg ML, Liu PY, Wilczynski s, et al, &ldquo;Phase II Trial of Vinorelbine for Relapsed Ovarian Cancer: A Southwest Oncology Group Study,&rdquo;",
"      <i>",
"       Gynecol Oncol",
"      </i>",
"      , 2004, 95(3):506-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/15581954/pubmed\" id=\"15581954\" target=\"_blank\">",
"        15581954",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Santoro A, Magagnoli M, Spina M, et al, &ldquo;Ifosfamide, Gemcitabine, and Vinorelbine: A New Induction Regimen for Refractory and Relapsed Hodgkin's Lymphoma,&rdquo;",
"      <i>",
"       Haematologica",
"      </i>",
"      , 2007, 92(1):35-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/17229633/pubmed\" id=\"17229633\" target=\"_blank\">",
"        17229633",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schulmeister L, \"Extravasation Management: Clinical Update,\"",
"      <i>",
"       Semin Oncol Nurs",
"      </i>",
"      , 2011, 27(1):82-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/21255716/pubmed\" id=\"21255716\" target=\"_blank\">",
"        21255716",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Stebbing J Powles T, McPherson K, et al, &ldquo;The Efficacy and Safety of Weekly Vinorelbine on Relapsed Malignant Pleural Mesothelioma,&rdquo;",
"      <i>",
"       Lung Cancer",
"      </i>",
"      , 2009, 63(1):94-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/18486273/pubmed\" id=\"18486273\" target=\"_blank\">",
"        18486273",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Superfin D, Iannucci AA, and Davies AM, &ldquo;Commentary: Oncologic Drugs in Patients With Organ Dysfunction: A Summary,&rdquo;",
"      <i>",
"       Oncologist",
"      </i>",
"      , 2007, 12(9):1070-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/17914077/pubmed\" id=\"17914077\" target=\"_blank\">",
"        17914077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Toso C and Lindley C, &ldquo;Vinorelbine: A Novel Vinca Alkaloid,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1995, 52(12):1287-304.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/7656116/pubmed\" id=\"7656116\" target=\"_blank\">",
"        7656116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Winton T, Livingston R, Johnson D, et al, \"Vinorelbine Plus Cisplatin Vs. Observation in Resected Non-Small-Cell Lung Cancer,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2005, 352(25):2589-97.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/15972865/pubmed\" id=\"15972865\" target=\"_blank\">",
"        15972865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zelek L, Barthier S, Riofrio M, et al, &ldquo;Weekly Vinorelbine is an Effective Palliative Regimen After Failure With Anthracyclines and Taxanes in Metastatic Breast Carcinoma,&rdquo;",
"      <i>",
"       Cancer",
"      </i>",
"      , 2001, 92(9):2267-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?0/59/953/abstract-text/11745280/pubmed\" id=\"11745280\" target=\"_blank\">",
"        11745280",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10046 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.25.216.6-41F16B85B6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_953=[""].join("\n");
var outline_f0_59_953=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708855\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234356\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234357\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234394\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234361\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234362\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234363\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234364\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720704\">",
"      Dosing: Adjustment for Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234335\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234320\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234338\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234400\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234336\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234390\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234403\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234392\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234341\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234324\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234388\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234329\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234353\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234331\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720023\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234370\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5720025\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324098\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234333\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234343\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234323\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F234340\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10046\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10046|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?8/8/8325?source=related_link\">",
"      Vinorelbine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_59_954="Valvular heart disease in patients with end-stage renal disease";
var content_f0_59_954=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Valvular heart disease in patients with end-stage renal disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/59/954/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/59/954/contributors\">",
"     Rochelle Cunningham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/59/954/contributors\">",
"     Mary Corretti, MD, FACC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/59/954/contributors\">",
"     William L Henrich, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/59/954/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/59/954/contributors\">",
"     Jeffrey S Berns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/59/954/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/59/954/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/59/954/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valvular heart disease is common in patients undergoing maintenance dialysis. Abnormalities include valvular and annular thickening, and calcification of any of the heart valves, but commonly the aortic and mitral valves, with the subsequent development of valvular regurgitation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    stenosis of the affected valve.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREDISPOSING FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many predisposing factors are associated with the development of valvular disease in dialysis patients, perhaps the most significant being the presence of secondary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Valvular calcification is also associated with an elevated calcium-phosphorus product, vascular calcification, hypercalcemia, and hyperphosphatemia, all findings that can occur in patients with marked secondary hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=see_link\">",
"     \"Indications for parathyroidectomy in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Valvular calcification may also be found in patients without secondary hyperparathyroidism, particularly among those with adynamic bone disease, older patients, and those who have undergone dialysis for a longer duration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The association with adynamic bone disease may be related to the use of calcitriol and calcium-containing phosphate binders, with increased calcium deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/8\">",
"     8",
"    </a>",
"    ]. Progressive disease may be attenuated in part by substituting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/44/40645?source=see_link\">",
"     sevelamer",
"    </a>",
"    for calcium-containing phosphate binders, as shown in a trial of 200 hemodialysis patients followed over a one year period [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional factors that may enhance the development of valvular heart disease in this patient population include the presence of one or more of the following conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypertension",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      Hyperlipidemia",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Malnutrition/inflammatory",
"      </span>",
"      complex",
"     </li>",
"     <li>",
"      Uremic milieu",
"     </li>",
"     <li>",
"      Hypertrophic cardiomyopathy",
"     </li>",
"     <li>",
"      Mitral valve prolapse",
"     </li>",
"     <li>",
"      High cardiac output states",
"     </li>",
"     <li>",
"      Anemia",
"     </li>",
"     <li>",
"      Infective endocarditis",
"     </li>",
"     <li>",
"      Arteriovenous fistulae",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of valvular calcification is also a marker of generalized vascular calcification in patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/11\">",
"     11",
"    </a>",
"    ]. Vascular calcification in this patient population is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=see_link\">",
"     \"Vascular calcification in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20185?source=see_link\">",
"     \"Biology of vascular calcification in renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     VALVULAR AND ANNULAR CALCIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to discussing the different clinical valvular abnormalities in patients with end-stage renal disease, it is helpful to first review the pathogenesis and pathology of calcification of the different heart valves; this underlies many of the clinical abnormalities observed in patients with end-stage renal disease, particularly valvular stenosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mitral annular calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mitral annular calcification (MAC) occurs in 10 to 50 percent of patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/1,7,12,13\">",
"     1,7,12,13",
"    </a>",
"    ]. As previously mentioned, it is associated with an elevated calcium-phosphorus product, vascular calcification, hypercalcemia, and hyperphosphatemia.",
"   </p>",
"   <p>",
"    MAC occurs earlier in patients with chronic renal failure than those without renal dysfunction, due in part to the dialysis procedure alone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/1\">",
"     1",
"    </a>",
"    ]. In one study, MAC was more common in younger (less than 60 years of age) than older dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/7\">",
"     7",
"    </a>",
"    ]. Since older dialysis patients are commonly dialyzed for fewer years because of a marked increase in mortality, MAC appears to occur more frequently in those dialyzed for a longer period of time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=see_link\">",
"     \"Patient survival and maintenance dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MAC is recognized echocardiographically as a uniform echodense rigid band, located posterior to the mitral leaflet and anterior to the left ventricular wall [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/3\">",
"     3",
"    </a>",
"    ]. It can extend along the endocardium of the posterior basal wall, and engulf and immobilize the posterior leaflet of the mitral valve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link&amp;anchor=H14#H14\">",
"     \"Echocardiographic evaluation of the mitral valve\", section on 'Mitral annular calcification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Aortic valve calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aortic valve calcification (AVC) is found in 25 to 55 percent of hemodialysis patients, occurring 10 to 20 years earlier than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/2,6,7,12-17\">",
"     2,6,7,12-17",
"    </a>",
"    ]. When adjusted for other cardiovascular risk factors, moderate chronic kidney disease is not significantly associated with aortic valve calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/18\">",
"     18",
"    </a>",
"    ]. Furthermore, it has been shown that the prevalence and severity of AVC and coronary artery calcium (CAC) are increased among patients with atherosclerotic causes of renal failure and do not vary with the severity of kidney disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aortic valve calcification is associated with factors similar to those associated with MAC. AVC occurs more frequently in patients who have received hemodialysis or peritoneal dialysis for a longer period of time and those with elevated serum parathyroid hormone, calcium,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    phosphorus levels [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/1-3,7,12,20,21\">",
"     1-3,7,12,20,21",
"    </a>",
"    ]. Other factors that promote the development of AVC include increasing age, enhanced mechanical stress on the valve cusps, minor congenital cusp inequalities, hypertension, inflammation, malnutrition, diabetes, and dyslipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/2,5,18,22-24\">",
"     2,5,18,22-24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tricuspid and pulmonic valve calcification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The occurrence of calcific deposits in the tricuspid and pulmonic valve annulus is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     VALVULAR THICKENING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Valvular thickening or sclerosis, which most commonly involves the aortic and mitral valves, is a frequent finding in hemodialysis patients. Among such patients, aortic and mitral valve sclerosis occur in 55 to 69 and 40 to 60 percent of individuals, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/2,7\">",
"     2,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although previously thought to be a nonspecific finding without clinical significance, valvular sclerosis is now recognized to be associated with progressive stenosis and increased cardiovascular mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/25\">",
"     25",
"    </a>",
"    ]. Prospective studies have found that valvular sclerosis may progress, usually gradually but occasionally rapidly, to clinically significant stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/2,26\">",
"     2,26",
"    </a>",
"    ]. In a Doppler echocardiographic study of 62 patients on hemodialysis, 34 had thickening of the aortic cusps; among these patients eight had aortic stenosis and eight had aortic regurgitation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/2\">",
"     2",
"    </a>",
"    ]. Twenty-five patients had thickening of the mitral annulus; among these patients, seven had mitral regurgitation and three had mitral stenosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=see_link\">",
"     \"Aortic valve sclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thickening typically involves the chordae tendineae, valve cusps, and leaflets [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/27\">",
"     27",
"    </a>",
"    ]. On gross examination, the chordae tendineae show irregular thickening and shortening. Histologically, the chordae tendineae appear as \"concentric rings of loose connective tissue around a central dense core.\"",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of valvular thickening is unclear. However, the presence of abnormal annular tissue, hyperparathyroidism, uremia, and subclinical infection are possible mechanisms [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/2,28\">",
"     2,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GENERAL ISSUES IN VALVULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal valvular abnormalities of clinical consequence that are observed in dialysis patients are regurgitant and stenotic lesions. Infective endocarditis, conduction abnormalities, and thromboembolism also may occur with these defects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of patients with valvular disease are similar in those with and without renal failure, but there are certain issues that are unique among dialysis patients. For example, valvular heart disease may be difficult to diagnose clinically via the physical examination because changing volume status makes the clinical assessment of murmurs difficult. Coexisting conditions, such as anemia and hypertension, also frequently exaggerate murmurs. In addition, valvular dysfunction may be associated with complications during hemodialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"     \"Auscultation of heart sounds\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=see_link\">",
"     \"Hemodynamic instability during hemodialysis: Overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another clinical issue related to volume status involves the presence of a diastolic murmur commonly heard in patients with end-stage renal disease. The exact origin of this murmur remains controversial. Although it was previously attributed to pericardial disease or aortic insufficiency, the murmur is now considered to arise from the pulmonic valve [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. Typically, the murmur is described as a diastolic, decrescendo murmur, that is blowing in quality and occurs immediately after the second heart sound. The maximal intensity is at the left sternal border or sometimes at the apex. It is best heard in the supine position, typically disappears after dialysis, and reappears when the patient becomes volume overloaded [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Echocardiography with Doppler flow analysis is an invaluable diagnostic screening tool for the presence of valvular heart disease; it is the modality of choice to detect and assess valvular dysfunction in patients with and without renal failure. Echocardiography can also evaluate left ventricular function and pericardial disease. However, prior to performing echocardiography, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend that the dry weight should be optimized [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=see_link\">",
"     \"Echocardiographic evaluation of the mitral valve\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two-dimensional echocardiography permits a real-time evaluation of the anatomy of the valve, subvalvular structures, annulus, and other cardiac structures. Doppler flow-analysis can also evaluate the degree of",
"    <span class=\"nowrap\">",
"     regurgitation/stenosis,",
"    </span>",
"    and flow dynamics. In patients with known valvular heart disease, serial echocardiograms are recommended to follow the progression of disease.",
"   </p>",
"   <p>",
"    Although echocardiography most commonly provides an accurate assessment of disease severity, cardiac catheterization may be necessary in patients with aortic stenosis or regurgitation, settings in which hemodynamic severity can be difficult to assess noninvasively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=see_link\">",
"     \"Hemodynamics of valvular disorders as measured by cardiac catheterization\"",
"    </a>",
"    .) Coronary angiography is principally needed to evaluate for coronary artery disease in patients who may undergo valve replacement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among dialysis patients, general therapeutic considerations for the treatment of valvular heart disease that are independent of the specific valvular defect should encompass the prevention and management of secondary hyperparathyroidism, hyperphosphatemia, hypercalcemia, increased",
"    <span class=\"nowrap\">",
"     calcium/phosphate",
"    </span>",
"    product, and hypertension. Effective prevention is particularly important since there are limited data to show that management after onset is effective [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/9,35\">",
"     9,35",
"    </a>",
"    ]; most investigators agree that the uremic milieu in association with other predisposing factors facilitate premature valvular heart disease and calcium deposition. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=see_link\">",
"     \"Treatment of hyperphosphatemia in chronic kidney disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=see_link\">",
"     \"Hypertension in dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Type of valve",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both bioprosthetic and mechanical valves, particularly in the dialysis patient, are at risk for endocarditis. Candidacy for long-term anticoagulation is also a factor in the clinical decision-making in selecting a valve, as it is required for all mechanical valves. However, accelerated dysfunction is common with bioprosthetic valves, while mechanical valves are associated with long-term function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link\">",
"     \"Complications of prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, the optimal replacement valve (independent of the exact anatomic location) is somewhat controversial. Many authors have traditionally favored a mechanical, not a bioprosthetic, valve; features that support the use of a mechanical valve are the enhanced risks of accelerated dysfunction and calcification of a bioprosthetic valve due to the uremic milieu.",
"   </p>",
"   <p>",
"    Subsequently, however, bioprosthetic valves have been used in hemodialysis patients with relatively good short-term results (less than five years) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/36\">",
"     36",
"    </a>",
"    ]. This was illustrated in a retrospective study of nearly 6000 dialysis patients in which survival at two years was similar among those who underwent cardiac valve replacement with a mechanical or bioprosthetic valve (40 percent for both groups) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/36\">",
"     36",
"    </a>",
"    ]. Benefits with bioprosthetic valves include a lower incidence of bleeding, thrombosis, and stroke (both early and late events) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/37-39\">",
"     37-39",
"    </a>",
"    ]. A meta-analysis that examined the heart valve prosthesis selection in patients with end-stage renal disease found no difference in survival between bioprosthetic and mechanical prosthetic valve types [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/40\">",
"     40",
"    </a>",
"    ]. However, as was demonstrated in earlier studies, valve replacement with bioprostheses was associated with fewer valve-related complications compared with mechanical prostheses. A single center retrospective study of 202 patients with end-stage renal disease undergoing valve replacement over a 12 year period found no difference in thirty-day mortality (19.9 percent) between bioprosthetic and mechanical valve replacements [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/41\">",
"     41",
"    </a>",
"    ]. However, 10 year survival was poor at 18 percent and was not influenced by the valve type implanted.",
"   </p>",
"   <p>",
"    To improve specific patient survival, decrease morbidity, and reduce symptoms, the type of valve chosen should be individualized, with the decision based upon the age, and clinical and functional status of the patient. Mechanical valves, particularly for the mitral valve, should be considered in younger and healthier patients; however, these individuals may be at a higher risk for bleeding and thrombotic complications. Careful consideration should be given in elderly patients, weighing such variables as the risk for bleeding, stroke, and the presence of hypercalcemia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hyperphosphatemia.",
"   </p>",
"   <p>",
"    In general, both mechanical and bioprosthetic valves can be used in dialysis patients, as recommended in the 2005",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Delivery of dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether the delivery of intensive doses of dialysis prior to or during surgery improves outcomes is unknown. Among the recommendations that have been made are daily dialysis for a few days prior to cardiac surgery and intraoperative hemodialysis during cardiac surgery. In general, dialysis should at least be provided the day before surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36601?source=see_link\">",
"     \"Medical management of the dialysis patient undergoing surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prognosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The survival of dialysis patients requiring valve replacement(s) (with or without coronary artery revascularization) is approximately 36 to 55 percent at five years, which is comparable to dialysis patients without valvular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/6,39\">",
"     6,39",
"    </a>",
"    ]. Many patients report clinical symptomatic improvement, as well as improvement in New York Heart Association (NYHA) classification [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/6,39\">",
"     6,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The presence of cardiac valvular calcification has been an important negative prognostic factor in some studies. Among nearly 200 peritoneal dialysis patients, valve calcification as detected by echocardiography at baseline was associated with a 2.5- and 5.4-fold increased risk of all-cause and cardiovascular death at follow-up at 1.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/42\">",
"     42",
"    </a>",
"    ]. Almost all patients (90 percent) with both valvular calcification and atherosclerotic vascular disease had died by one year, with death occurring in 21 and 23 percent of those with either abnormality alone and 13 percent of those with neither complication.",
"   </p>",
"   <p>",
"    However, in an Italian study of hemodialysis patients, the presence of calcifications was not an independent prognostic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/43\">",
"     43",
"    </a>",
"    ]. After adjustment for other cardiovascular risk factors, left ventricular mass index, and additional clinical characteristics, calcification failed to provide further independent predictive power.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     VALVULAR STENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stenosis of the aortic valve is the most common obstructive abnormality among hemodialysis patients, with the next most frequent lesion being mitral stenosis. By comparison, tricuspid and pulmonic stenosis are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stenotic heart valves in patients undergoing maintenance dialysis occur most commonly in association with annular calcification, which (as previously mentioned) is frequently due to hyperparathyroidism and an elevated serum calcium-phosphorous product. Thus, aortic and mitral stenosis are observed in association with AVC and MVC, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/2\">",
"     2",
"    </a>",
"    ]. Similar considerations apply to pulmonic and tricuspid stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among an increasingly older dialysis population, enhanced age alone is also a contributing factor to the development of aortic stenosis. Furthermore, aortic stenosis resulting from a bicuspid valve or rheumatic fever occurs at an earlier age among dialysis patients than those without renal failure because of factors associated with the uremic milieu, particularly calcium and phosphorous abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical manifestations, evaluation, and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the clinical manifestations and treatment of aortic, mitral, pulmonary, and tricuspid stenosis are similar in patients with and without renal failure, certain features are relatively unique among patients undergoing maintenance dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Aortic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 to 20 percent of dialysis patients have aortic stenosis, with hemodynamically significant stenosis eventually developing in 3 to 9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/6,14,17,45\">",
"     6,14,17,45",
"    </a>",
"    ]. In one study of hemodialysis patients, the estimated incidence of symptomatic aortic stenosis was 3.3 percent per year [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The degree of aortic stenosis is related to the degree of calcification [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/20,23\">",
"     20,23",
"    </a>",
"    ]. In addition, the rate of decrease in valve area is significantly higher among dialysis patients than those without renal failure (mean decrease of 0.23 versus 0.05 to 0.1 cm2 per year for uremic and nonuremic patients, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/14,17,45\">",
"     14,17,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=see_link\">",
"     \"Aortic valve area in aortic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with aortic stenosis are commonly asymptomatic for a prolonged period. Angina, syncope, and dyspnea eventually develop, followed by symptoms and signs of heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=see_link\">",
"     \"Natural history of aortic stenosis in adults\"",
"    </a>",
"    .) Progression is significantly more frequent in men than women [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/14,17,45\">",
"     14,17,45",
"    </a>",
"    ], with rapid progression to symptomatic aortic stenosis being associated with a significant decrease in survival.",
"   </p>",
"   <p>",
"    Among hemodialysis patients with aortic stenosis and left ventricular hypertrophy, aggressive ultrafiltration may lead to episodes of intradialytic hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/6\">",
"     6",
"    </a>",
"    ]. Excessive reduction of end-diastolic filling pressure may reduce cardiac output and coronary perfusion and result in myocardial ischemia and impaired oxygen delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/6\">",
"     6",
"    </a>",
"    ]. Clinically, this may result in chest pain, dyspnea, syncope, cardiac arrhythmias, and myocardial infarction during dialysis. Thus, the use of controlled ultrafiltration and careful attention to dry weight assessment is essential in the management of these patients.",
"   </p>",
"   <p>",
"    The principal sign of aortic stenosis is the characteristic systolic murmur, which is described as a systolic \"ejection\" murmur. It is typically heard best at the base of the heart (second intercostal space on the left) where it has a harsh quality. The murmur is transmitted well and equally to the carotid arteries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"     \"Auscultation of cardiac murmurs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among dialysis patients, however, systolic murmurs that are unrelated to aortic stenosis are common, resulting in diagnostic difficulties. Such murmurs include those due to a thickened aortic valve (but without hemodynamic compromise), mitral valve calcification, and increased blood flow (resulting from hypervolemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The modality of choice in the evaluation of possible aortic stenosis (as well as all other valvular modalities) is echocardiography and Doppler flow analysis. As previously mentioned, the rate of decrease in valve area is significantly higher among dialysis patients than those without renal failure. As a result, the",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommended that annual Doppler echocardiograms should be performed in the following patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/33\">",
"     33",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymptomatic waitlist patients with aortic valve area &le;1.0 cm2",
"     </li>",
"     <li>",
"      Other dialysis patients who are suitable candidates for aortic valve replacement based on overall clinical status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=see_link\">",
"     \"Clinical features and evaluation of aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac catheterization may be necessary in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, among patients in whom valve replacement is possible, coronary angiography is required to evaluate for coronary artery disease.",
"   </p>",
"   <p>",
"    The timing of valve replacement is similar in patients with or without renal failure. However, given that even mild disease with noncritical stenosis may result in significant cardiovascular morbidity among dialysis patients, early referral for valve replacement may be indicated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=see_link\">",
"     \"Indications for valve replacement in aortic stenosis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Many authors feel that the replacement valve should be a mechanical rather than a bioprosthetic valve. However, the decision should be made on an individual basis since equivalent results have been noted with the two types of valves [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/36,38,39\">",
"     36,38,39",
"    </a>",
"    ]. Although it may be more difficult to maintain anticoagulation in these patients when a mechanical valve is implanted, accelerated valve calcification is likely with a tissue prosthesis.",
"   </p>",
"   <p>",
"    Neither the 2008 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    nor the 2007 European Society of Cardiology guidelines on the management of valvular heart disease made specific recommendations on the choice of valve in patients with aortic stenosis who have end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11865?source=see_link&amp;anchor=H3#H3\">",
"     \"Surgical valve replacement in aortic stenosis in adults\", section on 'Mechanical versus bioprosthetic valve'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Mitral stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among dialysis patients, mitral stenosis is most commonly due to mitral annular calcification, rather than rheumatic fever [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/2,49\">",
"     2,49",
"    </a>",
"    ]. Data on prevalence are limited, but a review of 62 hemodialysis patients found mitral stenosis in three [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mitral stenosis can be associated with a variety of symptoms and signs that are primarily related to the severity of the valvular stenosis as reflected by the cardiac output, pulmonary pressures, and pulmonary vascular resistance. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=see_link\">",
"     \"Pathophysiology, clinical features, and evaluation of mitral stenosis\"",
"    </a>",
"    .) Hemodialysis may improve clinical symptoms by reducing preload; however, treatment requires careful assessment of dry weight and prevention of excessive ultrafiltration which can reduce ventricular filling across the stenotic mitral valve. Antibiotic prophylaxis should also be considered in appropriate settings (see",
"    <a class=\"local\" href=\"#H26\">",
"     'Infective endocarditis'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Rate control is important in patients with MS who develop atrial tachyarrhythmias since a rapid heart rate can further impair ventricular filling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4697?source=see_link\">",
"     \"Medical management and indications for intervention in mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Percutaneous mitral balloon valvotomy generally provides relief of symptoms in patients with mitral stenosis if the valve morphology is favorable. However, the use of this technique is generally contraindicated in patients with significant valvular and subvalvular calcification, mitral regurgitation, and left atrial or left atrial appendage clot. In such cases, open commissurotomy, valve reconstruction, or mitral valve replacement is preferable [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=see_link\">",
"     \"Percutaneous mitral balloon valvotomy for mitral stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=see_link\">",
"     \"Surgical management of mitral stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Pulmonic stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcific pulmonic deposits, when present, are often associated with pulmonic valve stenosis in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/50\">",
"     50",
"    </a>",
"    ]. This is usually accompanied by increased right ventricular systolic pressure and eventually right ventricular hypertrophy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=see_link\">",
"     \"Clinical manifestations and diagnosis of pulmonic stenosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12727?source=see_link\">",
"     \"Natural history and treatment of pulmonic stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     VALVULAR REGURGITATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A high prevalence of mitral, tricuspid, and aortic regurgitation is observed in dialysis patients [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/2,7\">",
"     2,7",
"    </a>",
"    ]. Mitral regurgitation is most common [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/7,52\">",
"     7,52",
"    </a>",
"    ]. In a series of 75 patients with a mean age of 59 years, for example, valvular regurgitation of the mitral, tricuspid, and aortic valves occurred in 95, 65, and 38 percent of patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/7\">",
"     7",
"    </a>",
"    ]. Additional findings included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Moderate and severe regurgitation of the mitral valve occurred in 27 and 13 percent of patients, respectively.",
"     </li>",
"     <li>",
"      Moderate and severe regurgitation of the tricuspid valve occurred in 13 and 5 percent of patients, respectively.",
"     </li>",
"     <li>",
"      Moderate aortic regurgitation was present in 4 percent of patients, while the incidence of severe aortic regurgitation was not reported.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevalence and degree of regurgitation varies with volume status, degree of left ventricular function, and medications administered (particularly antihypertensive agents), with changes in volume status being the most significant. One study of 21 hemodialysis patients with both mitral and tricuspid valve regurgitation assessed whether valvular insufficiency disappeared with aggressive ultrafiltration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/53\">",
"     53",
"    </a>",
"    ]. After intensified sessions resulting in a decrease in body weight of approximately 5.4 kg, mitral and tricuspid regurgitation vanished in 13 and 14 patients, respectively. Among those with persistent abnormalities, the degree of regurgitation was much less severe. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=see_link\">",
"     \"Functional mitral regurgitation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Etiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disappearance of regurgitant lesions with aggressive volume and blood pressure control suggests that most valvular insufficiency in dialysis patients is \"functional\" in origin. Valvular calcification appears to be responsible for most other cases, while infective endocarditis may also result in a regurgitant lesion (see below). In addition, mitral and aortic regurgitation may be more common in polycystic kidney disease, the former due in part to a possibly enhanced incidence of mitral valve prolapse [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/54\">",
"     54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=see_link\">",
"     \"Extrarenal manifestations of autosomal dominant polycystic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Clinical manifestations, evaluation, and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of regurgitant lesions are described in detail separately. (See appropriate topic reviews). However, there are issues that are unique to patients with end-stage renal disease. Compared with patients without renal failure, the management of regurgitant lesions in dialysis patients, particularly mitral and tricuspid regurgitation, should focus upon volume and blood pressure control. Aortic regurgitation is also worsened in the setting of elevated systolic pressure and increased afterload conditions. Aggressive ultrafiltration to attain clinical dry weight and optimal blood pressure control (with antihypertensive medications if necessary) should be therapeutic goals in these patients. The attainment of optimal intravascular volume may eliminate or severely reduce regurgitant valvular lesions, as well as diminish the clinical murmurs associated with these lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, more aggressive ultrafiltration does not always improve the clinical status of the patient. This finding may signal more advanced ventricular dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     INFECTIVE ENDOCARDITIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infective endocarditis (IE) occurs in approximately 3 percent of patients receiving hemodialysis, and approximately 9 percent of those with an infected access [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/55\">",
"     55",
"    </a>",
"    ]. Thus, the presence of a vascular access is a significant risk factor for the development of IE, including a primary arteriovenous fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/56-58\">",
"     56-58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most data related to IE in dialysis patients are derived from relatively small studies. The following are the two largest reports describing the clinical features of patients with end-stage renal disease and IE:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 40 dialysis patients with definite endocarditis, access types were an AV fistula, intravenous catheter, and polytetrafluoroethylene graft in 60, 30, and 18 percent, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/59\">",
"       59",
"      </a>",
"      ]. The mitral valve, aortic valve, or both were infected in 53, 20, and 20 percent, respectively.",
"     </li>",
"     <li>",
"      In another series of 28 dialysis patients with 30 episodes of endocarditis, the source of sepsis was related to a tunnel catheter, AV fistula, polytetrafluoroethylene graft, and non-tunneled catheter in 48, 32, 12, and 4 percent of patients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/57\">",
"       57",
"      </a>",
"      ]. Infection of the mitral valve, aortic valve, or both valves occurred in 41, 38, and 17 percent, respectively. Over one-half of affected patients had an abnormal valve, frequently calcified, prior to the valve infection.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    IE is also a known complication of mitral annular calcification (MAC). In one report, IE occurred in approximately 4 percent of patients with this abnormality [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aside from the numerous reasons for antibiotic prophylaxis in hemodialysis patients, patients with MAC are at increased risk for IE; routine antibiotic prophylaxis is therefore recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The short and long-term survival of dialysis patients with IE is poor, and has not improved over time. In a retrospective United States study of over 13,000 patients, the in-hospital mortality rate for those with IE was 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/61\">",
"     61",
"    </a>",
"    ]. In addition, among those hospitalized between 1977 and 1991, between 1992 and 1996, and between 1997 and 2000, the survival rates at one year were 46, 41, and 38 percent, respectively, while the three year rates were 24, 21, and 18 percent, respectively. Similar poor outcomes were reported in an analysis from the HEMO study [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations and treatment of IE is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=see_link\">",
"     \"Diagnostic approach to infective endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     ADDITIONAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysis patients with valvular heart abnormalities are at an increased risk of developing conduction disturbances and thromboembolism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Arrhythmias and conduction abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several arrhythmias and conduction system abnormalities, such as supraventricular arrhythmias, sinus node dysfunction, atrioventricular (AV) nodal and intraventricular blocks, are common in patients with MAC and AVC with or without stenosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/35,60,63-67\">",
"     35,60,63-67",
"    </a>",
"    ]. This may be in part hemodynamically mediated, but calcification within the conduction system is probably more important [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Atrial fibrillation is a particularly common finding [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/60\">",
"     60",
"    </a>",
"    ]. In one study, for example, atrial fibrillation occurred in 29 percent of patients with MAC [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thromboembolism is another significant complication of MAC and AVC, with numerous reports of calcific emboli occurring in those with calcified valves [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/60,68-70\">",
"     60,68-70",
"    </a>",
"    ]. As with valvular infection, superimposed thrombus can form on the calcified annulus. The thrombotic or ulcerative changes that occur within heavily calcified valves when exposed to the intracardiac lumen can result in an erupted mass of calcium entering the systemic circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/60\">",
"     60",
"    </a>",
"    ]. Additional factors that contribute to calcific thromboemboli include the presence of cardiac arrhythmias and left atrial enlargement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thromboemboli in patients with MAC usually result in cerebral ischemia. By comparison, those with AVC experience relatively more episodes of retinal emboli, resulting in retinal artery occlusion and transient monocular blindness. This difference suggests that emboli in patients with AVC are relatively small in size [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other potential sources for stroke often coexist with valvular calcification; these include dilated cardiomyopathy with left atrial enlargement, infective endocarditis, intracardiac thrombosis, and cardiac arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/60,71,72\">",
"     60,71,72",
"    </a>",
"    ]. Atrial fibrillation, for example, has been found in 50 percent of patients with MAC and cerebral infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/59/954/abstract/71\">",
"     71",
"    </a>",
"    ]. The treatment of these patients is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Valvular heart disease is common in patients undergoing maintenance dialysis. Many predisposing factors are associated with the development of valvular disease in this population. These include secondary hyperparathyroidism, an elevated calcium-phosphorus product, vascular calcification, hypercalcemia, uremic milieu, hyperphosphatemia, and a host of other factors. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Predisposing factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among those with end-stage renal disease, mitral annular and aortic valve calcification occurs in 10 to 50 percent and 25 to 55 percent of patients, respectively. By comparison, the occurrence of tricuspid and pulmonic valvular calcification is rare. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Valvular and annular calcification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Valvular thickening or sclerosis of the aortic and mitral valve is a frequent occurrence in hemodialysis patients, occurring in 55 to 69 percent of individuals. Valvular sclerosis is associated with progressive stenosis and increased cardiovascular mortality. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Valvular thickening'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical diagnosis of valvular heart disease is difficult by physical exam secondary to the changing volume status of dialysis patients, presence of anemia, and hypertension. Thus, echocardiography with Doppler flow analysis is an invaluable diagnostic screening tool for the presence of valvular heart disease. General therapeutic considerations that are independent of the specific valvular defect should encompass the prevention and management of secondary hyperparathyroidism, hyperphosphatemia, hypercalcemia, increased",
"      <span class=\"nowrap\">",
"       calcium/phosphate",
"      </span>",
"      product, and hypertension. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'General issues in valvular disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Stenosis of the aortic valve is the most common obstructive abnormality among hemodialysis patients, with the next most frequent lesion being mitral stenosis. By comparison, tricuspid and pulmonic stenosis are rare. Although the clinical manifestations and treatment of aortic, mitral, pulmonary, and tricuspid stenosis are similar in patients with and without renal failure, certain features are relatively unique among patients undergoing maintenance dialysis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Valvular stenosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A high prevalence of mitral, tricuspid, and aortic regurgitation is observed in dialysis patients. The disappearance of regurgitant lesions with aggressive volume and blood pressure control suggests that most valvular insufficiency in dialysis patients is \"functional\" in origin and aggressive ultrafiltration to attain clinical dry weight and optimal blood pressure control should be therapeutic goals in dialysis patients. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Valvular regurgitation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infective endocarditis, arrhythmias, conduction abnormalities, and thromboembolism are significant issues in dialysis patients with valvular abnormalities. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Infective endocarditis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H27\">",
"       'Additional complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/1\">",
"      Forman MB, Virmani R, Robertson RM, Stone WJ. Mitral anular calcification in chronic renal failure. Chest 1984; 85:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/2\">",
"      Straumann E, Meyer B, Misteli M, et al. Aortic and mitral valve disease in patients with end stage renal failure on long-term haemodialysis. Br Heart J 1992; 67:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/3\">",
"      Nestico PF, Depace NL, Morganroth J, et al. Mitral annular calcification: clinical, pathophysiology, and echocardiographic review. Am Heart J 1984; 107:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/4\">",
"      Rubel JR, Milford EL. The relationship between serum calcium and phosphate levels and cardiac valvular procedures in the hemodialysis population. Am J Kidney Dis 2003; 41:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/5\">",
"      Kajbaf S, Veinot JP, Ha A, Zimmerman D. Comparison of surgically removed cardiac valves of patients with ESRD with those of the general population. Am J Kidney Dis 2005; 46:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/6\">",
"      London GM, Pannier B, Marchais SJ, Guerin AP. Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 2000; 11:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/7\">",
"      Stinebaugh J, Lavie CJ, Milani RV, et al. Doppler echocardiographic assessment of valvular heart disease in patients requiring hemodialysis for end-stage renal disease. South Med J 1995; 88:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/8\">",
"      Salusky IB, Goodman WG. Cardiovascular calcification in end-stage renal disease. Nephrol Dial Transplant 2002; 17:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/9\">",
"      Raggi P, Bommer J, Chertow GM. Valvular calcification in hemodialysis patients randomized to calcium-based phosphorus binders or sevelamer. J Heart Valve Dis 2004; 13:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/10\">",
"      Floege J. When man turns to stone: extraosseous calcification in uremic patients. Kidney Int 2004; 65:2447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/11\">",
"      Wang AY, Ho SS, Wang M, et al. Cardiac valvular calcification as a marker of atherosclerosis and arterial calcification in end-stage renal disease. Arch Intern Med 2005; 165:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/12\">",
"      Bryg RJ, Gordon PR, Migdal SD. Doppler-detected tricuspid, mitral or aortic regurgitation in end-stage renal disease. Am J Cardiol 1989; 63:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/13\">",
"      Varma R, Aronow WS, McClung JA, et al. Prevalence of valve calcium and association of valve calcium with coronary artery disease, atherosclerotic vascular disease, and all-cause mortality in 137 patients undergoing hemodialysis for chronic renal failure. Am J Cardiol 2005; 95:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/14\">",
"      Maher ER, Pazianas M, Curtis JR. Calcific aortic stenosis: a complication of chronic uraemia. Nephron 1987; 47:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/15\">",
"      Braun J, Oldendorf M, Moshage W, et al. Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/16\">",
"      Baglin A, Hanslik T, Vaillant JN, et al. Severe valvular heart disease in patients on chronic dialysis. A five-year multicenter French survey. Ann Med Interne (Paris) 1997; 148:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/17\">",
"      Ure&ntilde;a P, Malergue MC, Goldfarb B, et al. Evolutive aortic stenosis in hemodialysis patients: analysis of risk factors. Nephrologie 1999; 20:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/18\">",
"      Ix JH, Shlipak MG, Katz R, et al. Kidney function and aortic valve and mitral annular calcification in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2007; 50:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/19\">",
"      Piers LH, Touw HR, Gansevoort R, et al. Relation of aortic valve and coronary artery calcium in patients with chronic kidney disease to the stage and etiology of the renal disease. Am J Cardiol 2009; 103:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/20\">",
"      Maher ER, Young G, Smyth-Walsh B, et al. Aortic and mitral valve calcification in patients with end-stage renal disease. Lancet 1987; 2:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/21\">",
"      Gruppen MP, Groothoff JW, Prins M, et al. Cardiac disease in young adult patients with end-stage renal disease since childhood: a Dutch cohort study. Kidney Int 2003; 63:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/22\">",
"      Merjanian R, Budoff M, Adler S, et al. Coronary artery, aortic wall, and valvular calcification in nondialyzed individuals with type 2 diabetes and renal disease. Kidney Int 2003; 64:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/23\">",
"      Roberts WC. The structure of the aortic valve in clinically isolated aortic stenosis: an autopsy study of 162 patients over 15 years of age. Circulation 1970; 42:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/24\">",
"      Wang AY, Woo J, Wang M, et al. Association of inflammation and malnutrition with cardiac valve calcification in continuous ambulatory peritoneal dialysis patients. J Am Soc Nephrol 2001; 12:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/25\">",
"      Otto CM, Lind BK, Kitzman DW, et al. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med 1999; 341:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/26\">",
"      Cosmi JE, Kort S, Tunick PA, et al. The risk of the development of aortic stenosis in patients with \"benign\" aortic valve thickening. Arch Intern Med 2002; 162:2345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/27\">",
"      D'Cruz I, Panetta F, Cohen H, Glick G. Submitral calcification or sclerosis in elderly patients: M mode and two dimensional echocardiography in \"mitral anulus calcification\". Am J Cardiol 1979; 44:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/28\">",
"      Abrahams C, D'Cruz I, Kathpalia S. Abnormalities in the mitral valve apparatus in patients undergoing long-term hemodialysis. Autopsy and echocardiographic correlation. Arch Intern Med 1982; 142:1796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/29\">",
"      Masani NN, Miyawaki N, Maesaka JK. A patient with an uncommon etiology of intradialytic hypotension. Semin Dial 2005; 18:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/30\">",
"      Barratt LJ, Robinson MA, Whitford JA, Lawrence JR. The diastolic murmur of renal failure. N Engl J Med 1976; 295:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/31\">",
"      Alexander WD, Polak A. Early diastolic murmurs in end-stage renal failure. Br Heart J 1977; 39:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/32\">",
"      P&eacute;res JE, Smith CA, Meltzer VN. Pulmonic valve insufficiency: a common cause of transient diastolic murmurs in renal failure. Ann Intern Med 1985; 103:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/33\">",
"      K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis 2005; 45:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/34\">",
"      Carabello BA, Crawford FA Jr. Valvular heart disease. N Engl J Med 1997; 337:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/35\">",
"      Raine AE. Acquired aortic stenosis in dialysis patients. Nephron 1994; 68:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/36\">",
"      Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients in the United States with prosthetic heart valves: should ACC/AHA practice guidelines on valve selection be modified? Circulation 2002; 105:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/37\">",
"      Lamberti JJ, Wainer BH, Fisher KA, et al. Calcific stenosis of the porcine heterograft. Ann Thorac Surg 1979; 28:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/38\">",
"      Kaplon RJ, Cosgrove DM 3rd, Gillinov AM, et al. Cardiac valve replacement in patients on dialysis: influence of prosthesis on survival. Ann Thorac Surg 2000; 70:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/39\">",
"      Lucke JC, Samy RN, Atkins BZ, et al. Results of valve replacement with mechanical and biological prostheses in chronic renal dialysis patients. Ann Thorac Surg 1997; 64:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/40\">",
"      Chan V, Chen L, Mesana L, et al. Heart valve prosthesis selection in patients with end-stage renal disease requiring dialysis: a systematic review and meta-analysis. Heart 2011; 97:2033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/41\">",
"      Thourani VH, Sarin EL, Keeling WB, et al. Long-term survival for patients with preoperative renal failure undergoing bioprosthetic or mechanical valve replacement. Ann Thorac Surg 2011; 91:1127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/42\">",
"      Wang AY, Wang M, Woo J, et al. Cardiac valve calcification as an important predictor for all-cause mortality and cardiovascular mortality in long-term peritoneal dialysis patients: a prospective study. J Am Soc Nephrol 2003; 14:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/43\">",
"      Panuccio V, Tripepi R, Tripepi G, et al. Heart valve calcifications, survival, and cardiovascular risk in hemodialysis patients. Am J Kidney Dis 2004; 43:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/44\">",
"      Roberts WC, Waller BF. Effect of chronic hypercalcemia on the heart. An analysis of 18 necropsy patients. Am J Med 1981; 71:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/45\">",
"      Castro L, H&ouml;fling B, H&auml;ssler R, et al. Progression of coronary and valvular heart disease in patients on dialysis. Trans Am Soc Artif Intern Organs 1985; 31:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/46\">",
"      Michel PL. Aortic stenosis in chronic renal failure patients treated by dialysis. Nephrol Dial Transplant 1998; 13 Suppl 4:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/47\">",
"      Bonow RO, Carabello BA, Chatterjee K, et al. 2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52:e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/48\">",
"      Vahanian A, Baumgartner H, Bax J, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/49\">",
"      D'Cruz IA, Madu EC. Progression to calcific mitral stenosis in end-stage renal disease. Am J Kidney Dis 1995; 26:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/50\">",
"      Roberts WC, Mason DT, Morrow AG, Braunwald E. Calcific pulmonic stenosis. Circulation 1968; 37:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/51\">",
"      Roberts WC, Perloff JK. Mitral valvular disease. A clinicopathologic survey of the conditions causing the mitral valve to function abnormally. Ann Intern Med 1972; 77:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/52\">",
"      Lavie CJ, Hebert K, Cassidy M. Prevalence and severity of Doppler-detected valvular regurgitation and estimation of right-sided cardiac pressures in patients with normal two-dimensional echocardiograms. Chest 1993; 103:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/53\">",
"      Cirit M, Ozkahya M, Cinar CS, et al. Disappearance of mitral and tricuspid regurgitation in haemodialysis patients after ultrafiltration. Nephrol Dial Transplant 1998; 13:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/54\">",
"      Lumiaho A, Ik&auml;heimo R, Miettinen R, et al. Mitral valve prolapse and mitral regurgitation are common in patients with polycystic kidney disease type 1. Am J Kidney Dis 2001; 38:1208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/55\">",
"      De Rossi SS, Glick M. Dental considerations for the patient with renal disease receiving hemodialysis. J Am Dent Assoc 1996; 127:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/56\">",
"      Robinson DL, Fowler VG, Sexton DJ, et al. Bacterial endocarditis in hemodialysis patients. Am J Kidney Dis 1997; 30:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/57\">",
"      Doulton T, Sabharwal N, Cairns HS, et al. Infective endocarditis in dialysis patients: new challenges and old. Kidney Int 2003; 64:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/58\">",
"      Nucifora G, Badano LP, Viale P, et al. Infective endocarditis in chronic haemodialysis patients: an increasing clinical challenge. Eur Heart J 2007; 28:2307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/59\">",
"      Spies C, Madison JR, Schatz IJ. Infective endocarditis in patients with end-stage renal disease: clinical presentation and outcome. Arch Intern Med 2004; 164:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/60\">",
"      Fulkerson PK, Beaver BM, Auseon JC, Graber HL. Calcification of the mitral annulus: etiology, clinical associations, complications and therapy. Am J Med 1979; 66:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/61\">",
"      Shroff GR, Herzog CA, Ma JZ, Collins AJ. Long-term survival of dialysis patients with bacterial endocarditis in the United States. Am J Kidney Dis 2004; 44:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/62\">",
"      Allon M, Radeva M, Bailey J, et al. The spectrum of infection-related morbidity in hospitalized haemodialysis patients. Nephrol Dial Transplant 2005; 20:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/63\">",
"      Nair CK, Sketch MH, Desai R, et al. High prevalence of symptomatic bradyarrhythmias due to atrioventricular node-fascicular and sinus node-atrial disease in patients with mitral anular calcification. Am Heart J 1982; 103:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/64\">",
"      Mellino M, Salcedo EE, Lever HM, et al. Echographic-quantified severity of mitral anulus calcification: prognostic correlation to related hemodynamic, valvular, rhythm, and conduction abnormalities. Am Heart J 1982; 103:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/65\">",
"      Burnside JW, Desanctis RW. Bacterial endocarditis on calcification of the mitral anulus fibrosus. Ann Intern Med 1972; 76:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/66\">",
"      de Bono DP, Warlow CP. Mitral-annulus calcification and cerebral or retinal ischaemia. Lancet 1979; 2:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/67\">",
"      Osterberger LE, Goldstein S, Khaja F, Lakier JB. Functional mitral stenosis in patients with massive mitral annular calcification. Circulation 1981; 64:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/68\">",
"      Pomerance A. Pathological and clinical study of calcification of the mitral valve ring. J Clin Pathol 1970; 23:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/69\">",
"      Katsamakis G, Lukovits TG, Gorelick PB. Calcific cerebral embolism in systemic calciphylaxis. Neurology 1998; 51:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/70\">",
"      Li Y, Muench A, McGregor DH, Wiegmann TB. Cerebral, myocardial and cutaneous ischemic necrosis associated with calcific emboli from aortic and mitral valve calcification in a patient with end-stage renal disease. Clin Nephrol 2002; 57:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/71\">",
"      Cardiogenic brain embolism. Cerebral Embolism Task Force. Arch Neurol 1986; 43:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/59/954/abstract/72\">",
"      Nishimura M, Hashimoto T, Kobayashi H, et al. The high incidence of left atrial appendage thrombosis in patients on maintenance haemodialysis. Nephrol Dial Transplant 2003; 18:2339.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1909 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-A7177AF1CA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_954=[""].join("\n");
var outline_f0_59_954=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREDISPOSING FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      VALVULAR AND ANNULAR CALCIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mitral annular calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Aortic valve calcification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tricuspid and pulmonic valve calcification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      VALVULAR THICKENING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GENERAL ISSUES IN VALVULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Type of valve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Delivery of dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      VALVULAR STENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical manifestations, evaluation, and treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      VALVULAR REGURGITATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Etiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Clinical manifestations, evaluation, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      INFECTIVE ENDOCARDITIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      ADDITIONAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Arrhythmias and conduction abnormalities",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1208?source=related_link\">",
"      Aortic valve area in aortic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/24/38279?source=related_link\">",
"      Aortic valve sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/45/20185?source=related_link\">",
"      Biology of vascular calcification in renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21706?source=related_link\">",
"      Clinical features and evaluation of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/62/39910?source=related_link\">",
"      Clinical manifestations and diagnosis of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/41/32409?source=related_link\">",
"      Echocardiographic evaluation of the mitral valve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/33/30233?source=related_link\">",
"      Extrarenal manifestations of autosomal dominant polycystic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/36/9799?source=related_link\">",
"      Functional mitral regurgitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/32/31240?source=related_link\">",
"      Hemodynamic instability during hemodialysis: Overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/41/3737?source=related_link\">",
"      Hemodynamics of valvular disorders as measured by cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/46/20202?source=related_link\">",
"      Hypertension in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/3/9273?source=related_link\">",
"      Indications for parathyroidectomy in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/8/31881?source=related_link\">",
"      Indications for valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/37/4697?source=related_link\">",
"      Medical management and indications for intervention in mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36601?source=related_link\">",
"      Medical management of the dialysis patient undergoing surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/27/12727?source=related_link\">",
"      Natural history and treatment of pulmonic stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30551?source=related_link\">",
"      Natural history of aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13610?source=related_link\">",
"      Pathophysiology, clinical features, and evaluation of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/13/37082?source=related_link\">",
"      Patient survival and maintenance dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/45/33497?source=related_link\">",
"      Percutaneous mitral balloon valvotomy for mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/4/17480?source=related_link\">",
"      Surgical management of mitral stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/37/11865?source=related_link\">",
"      Surgical valve replacement in aortic stenosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/57/33690?source=related_link\">",
"      Treatment of hyperphosphatemia in chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/20/17738?source=related_link\">",
"      Vascular calcification in chronic kidney disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_59_955="Nonmotor features PD PI";
var content_f0_59_955=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F53518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F53518&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nonmotor symptoms of Parkinson disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Cognitive dysfunction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psychosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mood disorders (depression, anxiety, apathy/abulia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sleep disturbances",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fatigue",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Autonomic dysfunction (urinary urgency/frequency, constipation, orthostasis, erectile dysfunction)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Olfactory dysfunction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pain and sensory disturbances",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dermatologic findings (seborrhea)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_955=[""].join("\n");
var outline_f0_59_955=null;
var title_f0_59_956="Prevalence of HSV vs bacterial meningitis in neonates";
var content_f0_59_956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57037&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Prevalence of herpes simplex virus (HSV) infection versus bacterial meningitis in neonates with cerebrospinal fluid (CSF) pleocytosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Clinical characteristic(s)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Number of patients",
"      </td>",
"      <td class=\"subtitle1\">",
"       HSV percent (95% CI)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Bacterial meningitis, percent (95% CI)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       Neonate (0-28 days)",
"      </td>",
"      <td>",
"       5817",
"      </td>",
"      <td>",
"       0.2 (0.1-0.3)",
"      </td>",
"      <td>",
"       0.4 (0.2-0.6)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       CSF pleocytosis",
"      </td>",
"      <td>",
"       472",
"      </td>",
"      <td>",
"       0.6 (0.1-1.9)",
"      </td>",
"      <td>",
"       3.2 (1.8-5.2)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &gt;50 percent PMNs*",
"      </td>",
"      <td>",
"       102",
"      </td>",
"      <td>",
"       0 (0-3.6)",
"      </td>",
"      <td>",
"       13.7 (7.7-22)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &gt;50 percent mononuclear cells",
"      </td>",
"      <td>",
"       330",
"      </td>",
"      <td>",
"       0.9 (0.2-2.6)",
"      </td>",
"      <td>",
"       0.3 (0-1.7)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_left\">",
"       CSF pleocytosis and fever",
"      </td>",
"      <td>",
"       204",
"      </td>",
"      <td>",
"       1 (0.1-3.5)",
"      </td>",
"      <td>",
"       5.4 (2.7-9.4)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &gt;50 percent PMNs*",
"      </td>",
"      <td>",
"       67",
"      </td>",
"      <td>",
"       0 (0-5.4)",
"      </td>",
"      <td>",
"       14.9 (7.4-25.7)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       &gt;50 percent mononuclear cells",
"      </td>",
"      <td>",
"       124",
"      </td>",
"      <td>",
"       1.6 (0.2-5.7)",
"      </td>",
"      <td>",
"       0.8 (0.0-4.4)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PMN: polymorphonuclear cells.",
"     <br>",
"      * 95 percent confidence intervals do not overlap.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Caviness AC, Demmler GJ, Almendarez Y, Selwyn BJ. The prevalence of neonatal herpes simplex virus infection compared with serious bacterial illness in hospitalized neonates. J Pediatr 2008; 153:164.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_956=[""].join("\n");
var outline_f0_59_956=null;
var title_f0_59_957="NCDB surg surv panc";
var content_f0_59_957=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F71233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F71233&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Five-year overall survival for resected pancreatic adenocarcinoma from the National Cancer Data Base",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\" colspan=\"3\">",
"       Surgical patients",
"      </td>",
"      <td class=\"subtitle1\" colspan=\"5\">",
"       Observed survival",
"      </td>",
"      <td class=\"subtitle1\" rowspan=\"2\">",
"       Median survival, months",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle2\">",
"       Number of patients",
"      </td>",
"      <td class=\"subtitle2\">",
"       Percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       1-year, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       2-year, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       3-year, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       4-year, percent",
"      </td>",
"      <td class=\"subtitle2\">",
"       5-year, percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IA",
"      </td>",
"      <td>",
"       1886",
"      </td>",
"      <td>",
"       8.8",
"      </td>",
"      <td>",
"       71.3",
"      </td>",
"      <td>",
"       50.2",
"      </td>",
"      <td>",
"       40.7",
"      </td>",
"      <td>",
"       34.7",
"      </td>",
"      <td>",
"       31.4",
"      </td>",
"      <td>",
"       24.1",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IB",
"      </td>",
"      <td>",
"       2364",
"      </td>",
"      <td>",
"       11.0",
"      </td>",
"      <td>",
"       67.3",
"      </td>",
"      <td>",
"       45.4",
"      </td>",
"      <td>",
"       35.3",
"      </td>",
"      <td>",
"       29.6",
"      </td>",
"      <td>",
"       27.2",
"      </td>",
"      <td>",
"       20.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIA",
"      </td>",
"      <td>",
"       3846",
"      </td>",
"      <td>",
"       17.9",
"      </td>",
"      <td>",
"       60.7",
"      </td>",
"      <td>",
"       34.9",
"      </td>",
"      <td>",
"       23.8",
"      </td>",
"      <td>",
"       18.4",
"      </td>",
"      <td>",
"       15.7",
"      </td>",
"      <td>",
"       15.4",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IIB",
"      </td>",
"      <td>",
"       7828",
"      </td>",
"      <td>",
"       36.4",
"      </td>",
"      <td>",
"       52.7",
"      </td>",
"      <td>",
"       23.8",
"      </td>",
"      <td>",
"       14.4",
"      </td>",
"      <td>",
"       10.2",
"      </td>",
"      <td>",
"       7.7",
"      </td>",
"      <td>",
"       12.7",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       III",
"      </td>",
"      <td>",
"       2850",
"      </td>",
"      <td>",
"       13.2",
"      </td>",
"      <td>",
"       44.5",
"      </td>",
"      <td>",
"       19.3",
"      </td>",
"      <td>",
"       11.0",
"      </td>",
"      <td>",
"       8.1",
"      </td>",
"      <td>",
"       6.8",
"      </td>",
"      <td>",
"       10.6",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       IV",
"      </td>",
"      <td>",
"       2738",
"      </td>",
"      <td>",
"       12.7",
"      </td>",
"      <td>",
"       19.2",
"      </td>",
"      <td>",
"       8.4",
"      </td>",
"      <td>",
"       5.3",
"      </td>",
"      <td>",
"       3.7",
"      </td>",
"      <td>",
"       2.8",
"      </td>",
"      <td>",
"       4.5",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       <strong>",
"        Total",
"       </strong>",
"      </td>",
"      <td>",
"       <strong>",
"        21,512",
"       </strong>",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"      <td>",
"       <strong>",
"        12.6",
"       </strong>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reference:",
"     <br>",
"      <ol>",
"       <li>",
"        Bilimoria KY, Bentrem DJ, Ko Cy, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007; 110(4):738-44, with permission of Wiley.",
"       </li>",
"      </ol>",
"      Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Seventh Edition (2010) published by Springer New York, Inc.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_957=[""].join("\n");
var outline_f0_59_957=null;
var title_f0_59_958="ABVD chemotherapy for Hodgkin lymphoma";
var content_f0_59_958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ABVD chemotherapy for Hodgkin lymphoma",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 28 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Doxorubicin",
"        </strong>",
"       </td>",
"       <td>",
"        25 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 50 mL normal saline (NS) and administer over three to five minutes or IV push through a peripheral line.",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Bleomycin",
"        </strong>",
"        *",
"       </td>",
"       <td>",
"        10 units/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        <p>",
"         Dilute in 50 mL NS and administer over 10 minutes or IV push through a peripheral line.",
"        </p>",
"        <p>",
"         Test dose of 2 units given one hour before full dose can be considered for the first cycle",
"         <sup>",
"          &Delta;",
"         </sup>",
"         .",
"        </p>",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Vinblastine",
"        </strong>",
"       </td>",
"       <td>",
"        6 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Administer over one minute.",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Dacarbazine",
"        </strong>",
"       </td>",
"       <td>",
"        375 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        <p>",
"         Central line: Dilute in 250 mL of 5 percent dextrose (D5W) and administer over 30 minutes.",
"        </p>",
"        <p>",
"         Peripheral line: Dilute in 500 mL of D5W and administer over 60 minutes.",
"        </p>",
"        <p>",
"         Dacarbazine should be protected from light.",
"        </p>",
"       </td>",
"       <td>",
"        Days 1 and 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        HIGH (&gt;90 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        A bleomycin test dose may be administered before the first cycle. Premedicate with acetaminophen prior to administration of the full bleomycin dose. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Doxorubicin and vinblastine are vesicants. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with G-CSF is generally not indicated, and G-CSF is avoided in some centers because of concerns that concurrent use may increase bleomycin lung toxicity. Refer to UpToDate topic on \"Bleomycin-induced lung injury\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A 25 percent dose reduction in bleomycin is recommended for patients with creatinine clearance 10 to 50 mL/min, and a 50 percent reduction for clearance &lt;10 mL/min. Chemotherapy dose adjustments for doxorubicin and vinblastine are needed in patients with cholestasis or AST/ALT abnormalities. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess CBC with differential weekly during treatment. Assess electrolytes, renal function, and liver function prior to each treatment cycle.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Cumulative doxorubicin dose should be monitored. Measure left ventricular ejection fraction prior to first cycle, then as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for respiratory complaints or unexplained findings on lung exam (eg, rales). Maximum bleomycin lifetime dose not to exceed 400 mg. Measure pulmonary diffusion capacity before first cycle and then per institutional policy. Refer to UpToDate topic on \"Bleomycin-induced lung injury\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose modifications for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        Hold treatment until the WBC count is &gt;2500/microL and the platelet count &gt;80,000/microL on the day of treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Pulmonary toxicity:",
"        </strong>",
"        Bleomycin should be discontinued in patients with documented or strongly sustpected bleomycin-induced lung injury. Refer to UpToDate topic on \"Bleomycin-induced lung injury\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neuropathy:",
"        </strong>",
"        For severe paresthesias and/or constipation, the dose of vinblastine should be reduced by 50 percent. Vinblastine should be discontinued permanently if an adynamic ileus occurs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; G-CSF: granulocyte-colony stimulating factors; AST: aspartate aminotransferase; ALT: alanine aminotransferase; CBC: complete blood count; WBC: white blood cell.",
"     <br/>",
"     * 1 mg bleomycin = 1 unit bleomycin.",
"     <br/>",
"     &Delta; A test dose of bleomycin before the first dose is recommended by the manufacturer",
"     <sup>",
"      [2]",
"     </sup>",
"     ; however, many institutions no longer perform this test dose. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Canellos GP, et al. N Engl J Med 1992; 327:1478.",
"      </li>",
"      <li>",
"       Blenoxane (bleomycin sulfate) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on January 3, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_958=[""].join("\n");
var outline_f0_59_958=null;
var title_f0_59_959="Adverse events of darbepoetin alfa and rHuEPO";
var content_f0_59_959=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78873&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 499px\">",
"   <div class=\"ttl\">",
"    Graph showing incidence of adverse events of darbepoetin alfa and rHuEPO",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 479px; height: 372px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This graph , which is derived from an integrated database of safety data, shows the proportion of patients reporting adverse events at an incidence of greater than 10 percent.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Nissenson, AR. Am J Kidney Dis 2001; 38:1390.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_59_959=[""].join("\n");
var outline_f0_59_959=null;
